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ABSTRACT 
 
The study sought to investigate adherence for people living with HIV who are on ART.  Since   
high levels of adherence of more than 95% are required to achieve the durable suppression of the 
viral load, the researcher finds it very important to find out whether the people are doing what is 
expected of them. While the rollout of antiretroviral (ARV) therapy has brought much 
excitement and hope to both patients and practitioners in South Africa, it has also brought many 
new questions and challenges, including adherence. Adherence is therefore very crucial to the 
success of ART.  The research sought to investigate adherence in resource-poor settings.   
 
The research was conducted on patients attending Ithembalabantu clinic in Umlazi, Durban, 
Kwazulu Natal, South Africa.  Respondents were recruited as they come to the clinic to collect 
their medication. 
 
Triangulation of qualitative and quantitative research was used to collect data in the study.  The 
quantitative data involved 90 questionnaires.  The qualitative data involved 15 semi structured 
interviews. 
 
The results indicated that adherence to ART is very high and satisfactory among the sample 
population with 79% who never skipped or missed their medication and 64% who indicated that 
they followed their specific schedule all the time; and 88% of the respondents were aware of the 
dangers of sleeping without a condom more especially while on ART.  The results showed that 
there is a very high level of condom usage among the sample population.  The respondents from 
the in-depth interviews indicated that participants are not affected by the factors that lead to poor 
adherence.   
 
The only problem that needs urgent attention is the importance of the knowledge of viral load 
and CD4 count.  The participants seemed to be confused by the two and most of them did not 
know why they are measured.   
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 OPSOMMING 
 
Hierdie studie het gepoog om vlakke van getrouheid aan volgehoue deelneming te ondersoek 
onder MIV positiewe persone wie antiretrovirale terapie (ART) ontvang. Omdat hoë vlakke van 
getrouheid van meer as 95% nodig is om duursame suppressie van die virale lading to bereik, 
voel die navorser dat dit baie belangrek is om uit te vind of persone doen wat van hulle verwag 
word.  Terwyl die uitrol van ART opgewondenheid en hoop vir beide pasiënte en praktisyne in 
Suid-Afrika gebring het, het dit ook baie nuwe vrae en uitdagings gebring, getrouheid ingesluit. 
Getrouheid is dus beslissend vir die sukses van ART. Die navorsing het gepoog om getrouheid in 
hulpbron-swak areas te ondersoek.   
 
Die navorsing is uitgevoer op pasiënte wat die Ithembalabantu kliniek in Umlazi, Durban, 
Kwazulu Natal, Suid-Afrika bywoon.  Respondente is gewerf soos hulle na die kliniek toe 
gekom het om hul medikasie te kry.  
 
Triangulasie van kwalitatiewe en kwantitatiewe navorsing is gebruik om data in te samel.  Die 
kwantitatiewe data is deur vraelyste ingesamel en die kwalitatiewe data is deur 15 semi-
gestruktureerde onderhoude ingesamel. 
 
Die resultate het gewys dat getrouheid aan ART hoog en voldoende onder die steekproek 
populasie is met 79% wie nooit hul medikasie gemis het, 64% wie aangedui het dat hulle hul 
spesifieke skedule heeltyd volg, en 88% van die respondente is bewus van die gevaar van seks 
sonder 'n kondoom, veral vir persone op ART.  Die uitslae wys dat daar 'n hoë valk van 
kondoom gebruik onder die steekproef populasie is. Die respondente in die onderhoud groep is  
nie deur die faktore wat tot swak getrouheid lei geaffekteer nie.   
 
Die enigste probleem wat dringende aandag benodig is die belangrikheid van kennis van virale 
vrag en CD4 telling.  Dit het voorgekom asof die deelnemers deur die twee verwar word en 
meeste van hulle het nie geweet waarom hulle gemeet word nie.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction 
 
Since HIV was discovered in the human body in 1981, it still continues to be one of the most the 
destructive epidemics in human history.  More than 2.1 million people have died from 
HIV/AIDS (UNAIDS, 2007).  Over 6800 persons become infected with HIV every day.   Over 
5700 persons die from AIDS, mostly because of inadequate access to HIV prevention and 
treatment services.  The estimated number of persons living with HIV/AIDS worldwide in 2007 
was 33.2 million, a reduction of 16 % compared with the estimate of 30.5 million published in 
2006 (UNAIDS, 2006).  HIV/AIDS hinders development in all countries with a high prevalence 
rate.  It also threatens health, economic and social progress.  It also reduces life expectancy or 
deepens poverty (UNAIDS, 2004a). 
 
In the 2005 World Summit Outcome (resolution 60/1), world leaders committed to a massive 
scaling up of HIV prevention, treatment and care with the aim of coming as close as possible to 
the goal of universal access to treatment by 2010 for all who need it.  Leaders of the Group of 
Eight countries express their strong support for working towards this goal. 
 
In response to the request of General Assembly contained in its resolution 60/224, the secretariat 
and co-sponsors of the Joint United Nations Programme on HIV/AIDS (UNAIDS) have helped 
to facilitate inclusive, country-led processes to develop practical strategies for moving towards 
universal access (UNAIDS, 2006). 
 
The country processes build on earlier efforts, such as ‘3 by 5’ (treating 3 million people by 2005 
initiative) to expand HIV treatment.  The WHO strategy was launched in 2003 to provide 
antiretroviral therapy to people living with HIV/AIDS in developing countries.  A number of key 
challenges that stand in the way of scaling up towards universal access emerged from 
consultations.   
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Financing to implement the AIDS plan is adequate and funding is always unpredictable and of 
too short duration, reducing the ability of governments to sustain the delivery of AIDS 
programmes.  UNAIDS has identified six major requirements for reaching the common goal in 
helping to overcome major obstacles impeding countries from scaling up integrated AIDS 
programmes and moving towards universal access (UNAIDS, 2007). 
 
The number of people on ART in sub-Saharan Africa has surpassed one million for the first time, 
a ten-fold increase in treatment access in the region since December 2003 (UNAIDS,2006).  In 
low-and-middle-income countries, just over 1.6 million persons were receiving antiretroviral 
therapy at the end of June 2006, a 24% increase over the 1.3 million who had access to the drugs 
in December 2006, and four times the 400,000 people receiving treatment in these countries in 
December 2003 (UNAIDS,2006).  To date, 14 low and middle-income countries have met the ‘3 
by 5’. Out of 49 WHO/UNAIDS ‘focus countries’ in the ‘ 3 by 5’ initiatives, 40 have established 
national targets for treatment access, and 34 are developing or has completed implementation 
plans. 
 
South Africa launched its planned scale-up in November 2003.  One of the Operational Plan 
goals is to provide comprehensive care and treatment of the National health system in South 
Africa (DOH, 2003).  The South African Operational Comprehensive Care and Treatment for 
People Living with HIV/AIDS aimed to have 381,177 people on Government funded ART’s by 
2005-2006.  Only 85,000 people in the public sector were receiving treatment by September 
2005.  The latest WHO estimate is 460, 000 South Africans receiving ART’s at the end of 
December 2007 equating to 28 % of those in need of treatment.  
 
Antiretroviral therapy is the treatment that is available for People Living with HIV/AIDS.  A 
patient who adheres to this treatment has a chance of living for a long time.  Lack of strict 
adherence to highly active antiretroviral ARV therapy is considered to be one of the key 
challenges to AIDS care worldwide.  Estimates of the average rate of non-adherence with ARV 
therapy range from 50%-70% in many different social and cultural settings and the risk 
associated with non-adherence are extensive at both individual and societal levels.   
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Non-adherence of antiretroviral treatment is a problem.  It may result in rapid rebound of plasma 
viraemia, leading to treatment failure.  Adherence is therefore perceived as a significant barrier 
to delivery of ARV therapy in Sub-Saharan Africa and particularly South Africa.  I decided to 
investigate the rate or level of adherence and to measure the impact of various levels of non-
adherence on ARV therapy outcome. 
 
The main focus of this study is on adherence to ART at Ithembalabantu clinic at Umlazi.  
Adherence to ART is very important to prolong the lives of People Living with HIV/AIDS and 
also to avoid drug resistance. 
 
1.2 Background to the research 
 
Very few studies have been published relating to medication adherence to antiretroviral (ARV) 
treatment in resource-poor-settings and looking at particularly one of the clinics in KwaZulu 
Natal which is the most populous province in South Africa with the highest HIV-1 adult 
prevalence rate.   
 
1.2.1 The epidemiology of HIV/AIDS 
 
It is very difficult to determine how many people are infected with HIV and AIDS worldwide.  
The reason is that not many people come forward for testing; therefore it is too difficult to 
definitely diagnose HIV infection in the absence of HIV testing.  Poor surveillance systems in 
many countries also make reporting of detected cases harder.  Most available figures are, 
therefore, only estimates of the number of people infected with HIV.  All estimates indicate the 
lowest and the highest number of people possibly affected.  This study will use the median 
estimate that is derived from these numbers. 
 
1.2.2 The Global epidemic 
 
At the end of December 2007, an estimated 33.2 million were living with HIV worldwide 
(UNAIDS, 2007).  In 2007, 2.5 million people were newly infected with HIV (UNAIDS, 2007), 
2.1 million adults and 420,000 children under 15 years.  Out of the Global total People Living 
with HIV, 30.8 million are adults, 15.4 million women, and 2.1 million children under 15 years.  
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In 2007 also, 2.1 million people died because of AIDS related illnesses, 1.7 million adults and 
290,000 children under 15 years. 
 
1.2.3 The Sub Saharan epidemic 
 
At the end of 2007, an estimated 22 million of people were living with HIV in sub-Saharan 
Africa.  An estimated 1.9 million people were newly infected with HIV (UNAIDS, 2007). Two 
thirds (67%) of the global total of 33.2 million people with HIV live in this region, and three 
quarters (75%) of all deaths in 2007 occurred in the region.  Sub-Saharan Africa’s prevalence 
varies significantly from country to country in both scale and scope.  Adult National HIV 
prevalence is below 2% in several countries of west and central Africa, as well as in the horn of 
Africa, but in 2007 it exceeded 15% in seven Southern African countries, mostly in Central and 
East Africa (Cameroon, the Central African Republic, Gabon, Malawi, Mozambique, Uganda, 
and the United Republic of Tanzania). 
 
Recent epidemiological trends have shown that HIV in sub-Saharan Africa have stabilized, 
although often at very high levels, particularly in Southern Africa (UNAIDS, 2007).  
Additionally, in a growing number of countries, adult HIV prevalence appears to be falling.  For 
the region as a whole, women are disproportionately affected in comparison with men, with 
especially stark differences between the sexes in HIV prevalence among young people.  In 
Southern Africa, reductions in HIV prevalence are especially striking in Zimbabwe, where HIV 
prevalence in pregnant women attending antenatal clinics fell from 26% in 2002 to 18% in 2006. 
 
In Botswana a drop in HIV prevalence among pregnant 15-19 year olds (from 25% in 2001 to 
18% in 2006) suggests that the rates of new infections could be slowing (UNAIDS, 2006).    In 
Malawi and Zambia HIV have stabilized, amid some evidence of favorable behavior changes and 
signs of declining HIV prevalence among women using antenatal services in some urban areas.  
HIV data from antenatal clinics in South Africa suggests that, country’s HIV might be stabilizing 
but there is no evidence yet of major changes in HIV-related behavior.  The estimated 5.7 million 
South Africans living with HIV in 2007 made the country with the highest HIV prevalence in the 
world.  The 26% HIV prevalence found in adults in Swaziland in 2006 is the highest prevalence 
ever documented in a national population-based survey anywhere in the world. 
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In Lesotho and parts of Mozambique, HIV prevalence among pregnant women is increasing.  In 
some of the provinces in the central and southern zones of the country, report adult HIV 
prevalence exceeding 20% (UNAIDS, 2008).  HIV prevalence in the comparatively smaller 
epidemic in East Africa has either reached a plateau or is receding.  After dropping dramatically 
in the 1990s, adult national HIV prevalence in Uganda has stabilized at 5.4% but there are signs 
of a possible resurgence in sexual risk-taking that could cause the epidemic to grow.   
 
The proportion of adult men and women who say they had sex with a person who was not a 
spouse and did not live with the respondent has grown since 1995 (from 12% to 16% for women 
and 29% to 36% for men).   
 
The comparatively smaller HIV prevalence in West Africa is stable or are declining, as is the 
case for Burkina Faso, Cote d’Ivoire, and Mali.  In Cote d’Ivoire, HIV prevalence among 
pregnant women in urban areas fell from 10% in 2001 to 6.9% in 2005.  The largest prevalence 
in West Africa, in Nigeria, the continent’s most populous country have stabilized at 3.1 %, 
according to HIV infection trends among women attending antenatal clinics. 
 
1.2.4 The Epidemiology of HIV in South Africa and KwaZulu Natal 
 
With an estimated 5.5 million PLHA (UNAIDS, 2006), South Africa is the country with the 
largest number of infections in the world.  The country’s DOH estimated that 18.3 % of adults 
(15-49) are living with HIV in 2006 (DOH, 2007).  More than half (55%) of all South Africans 
infected with HIV reside in KwaZulu Natal and Gauteng provinces (Dorrington et al., 2006).  
 
The latest HIV data collected at the antenatal clinics suggest that HIV infection levels might be 
leveling off, with prevalence in pregnant women at 30% in 2005 and 29% in 2006 (DOH, 2007).  
The decrease in the percentage of young pregnant women (15-24 years) found to be infected 
with HIV also suggests a possible decline in the annual number of new infections.   
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The epidemic varies considerably between provinces.  HIV prevalence among pregnant women 
is highest in the populous KZN province (39%); lowest and highest prevalence has been found in 
parts of KZN.   For example, in Amajuba district, 47% of women attending antenatal clinics 
tested positive in 2006 (DOH, 2007), as did 51% of women aged 25-29 years who participated in 
earlier household-based HIV survey in the rural district of UMkhanyakude (Welz et al., 2007).  
In the rural district in the North of KZN, an HIV incidence of 8% was found in men and women 
aged 25-29 years.   
 
On the trends, and in the absence of effective programmes, it is estimated that two-thirds of the 
15-year-olds in that district could be infected with HIV by the time they reach their 35th birthday 
(Barnighausen et al., 2007).  Young women in South Africa face greater risks of becoming 
infected than men.  Among 15-24 year olds, women account for about 90% of new infections 
(Rehle et al., 2007).  HIV incidence is being found in men towards the upper end of this age 
group: in Northern KZN study, and estimated 8.8 % of men aged 24-29 years has been infected 
in the previous year (Barnighausen et al., 2007). 
 
An estimated 1.8 million South Africans have died from Aids-related diseases since the epidemic 
began (Dorrington et al., 2006).  Total annual deaths (from all causes) increased by 87 % from 
1997-2006 (from 316 505 to 591 213) (SSA, 2005 and 2006), with at least 40 % of those deaths 
estimated to be Aids-related (Bradshaw et al., 2004). 
 
Rising death rates lowered life expectancy at birth to 49 years for males and 52.5 years for 
females in 2006, and have contributed to the decline in the country’s population growth rate from 
1.25 % in 2001-2002 to more slightly more than 1 % in 2005-2006 (SSA, 2007). 
 
The major causes and determinants of the epidemic in SA are social and sexual networks. The 
context for these social and sexual networks is that of a newly democratic society emerging from 
a history of social disruption and racial and gender discrimination associated with inequitable 
distribution of resources as a result of Apartheid.   
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The inequitable distribution of resources massively disadvantaged the majority of the population.  
This has resulted in a bimodal society, which is also reflected in the spread of disease within the 
population. Poverty related diseases including HIV and AIDS, TB and Malaria affect mainly the 
previously disadvantaged sections of the population. 
 
1.2.5 The impact of HIV in SA 
The majority of people infected with HIV and AIDS are those who are already in their 
productive years.  In sub-Saharan Africa, people aged 15-49 have the highest productivity.  
Households depend on their labor for support.  HIV and AIDS, therefore has a profound impact 
of both the macro and micro levels of the economy (Sunter &Whiteside, 2000). 
 
The demographic impact of HIV and AIDS on the South African population is also apparent in 
statistics such as the under 5 mortality rate, which has increased from 65 deaths per 1000 births 
in 1990 to 75 deaths per 1000 births in 2006 (DOH,2006).  
 
Mortality rates in 1990 suggest that a 15-year old had a 29 % chance of dying before the age of 
60, but mortality rates in 2006 suggested that 15-year olds have a 56 % chance of dying before 
they reach 60.  Other estimates provided by the Actuarial Society of South Africa for 2006 
include:  
 1.8 million AIDS deaths occurred in South Africa, since the start of the epidemic. 
 Around 740 000 deaths occurred in 2006, of 350 000 were due to AIDS 
(approximately 950 AIDS-related deaths per day). 
 71 % of all deaths in the 15-49 age groups were due to AIDS. 
 Approximately 230 000 HIV-infected individuals were receiving antiretroviral 
treatment, and a further 540 000 were sick with AIDS but not receiving antiretroviral 
treatment. 
 300 000 children under the age of 18 experienced deaths of their mothers. 
 1.5 million children under the age of 18 were maternal or double orphans (i.e. had 
lost a mother or both parents), and 66 % of these children had been orphaned as the 
results of HIV and AIDS (ASSA, 2006). 
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The economy also is affected as the ILO demonstrated in 2004, and again with more recent data 
in 2006, that the rate of economic growth in countries heavily affected by HIV and AIDS has 
been reduced by the epidemic’s effect on labor supply, productivity and investment over the last 
decade or more.  According to the assessment, 3.7 million labor force participants aged 15-64 
years were living with HIV/AIDS or with AIDS in South Africa (ILO, 2006). 
 
Households and communities experience the immediate impact of HIV and AIDS, because 
families are the main caregivers for the sick and suffer AIDS-related financial hardships.  During 
the long period of illness caused by AIDS, the loss of income and cost of caring for a dying 
family member can impoverish households (Ashford, 2006).   
 
The problem of orphan and vulnerable children will persist for years, even with the expansion of 
prevention and treatment programmes.  Studies in several districts in South Africa found that the 
majority of orphans are being cared for by grandparents, family members or through self-care in 
child-headed households.  Orphans and Vulnerable Children are at high risk of HIV infection, as 
they face numerous materials, emotional and social problems.  They also face discrimination and 
stigma.  Many of them drop out of school due to the inability to pay school fees and also suffer 
from malnutrition and ill health and are in a danger of exploitation and abuse (UNAIDS, 
UNICEF, USAID 2004).   
 
Less emphasis has been given to the psychosocial impacts of the diseases which are related to 
illness and death of parents, children and other family members; caring for people who are ill 
and dying of AIDS, and living with and coping with an HIV positive diagnosis.  Psychological 
distress and psychological disorders are also more prevalent amongst PLHA, and the importance 
of mental health programmes in relation to HIV and AIDS has long been overlooked (Baingana 
et al., 2004).  
 
 
 
 
  
9
HIV and AIDS affect both the supply and demand of health care systems.  On the supply side of 
health systems, the human resources effects of HIV are two-fold: the stress and morale impacts 
of rapidly changing epidemiological, demand and mortality profiles in patients caused by HIV 
and AIDS, and HIV infection in providers themselves.  In a survey of 512 public sector workers 
in four provinces, 16.3 % were HIV infected (Shisana et al., 2003).  An HIV prevalence study at 
the Helen Joseph and Coronation Hospitals with 91 % response rate, found that 13.7 % of 644 
nurses were HIV infected and 19% had AIDS defining CD4 cell counts (Connelly et al., 2007). 
 
The epidemic also affects the supply and demand for primary and secondary schools.  On the 
supply side, infected teachers will eventually become chronically ill, with increased absenteeism, 
lower morale and productivity.  A South African Education Sector study found a sero-prevalence 
of 12.7 % among teachers and significant gender, racial and geographical differences (Shisana et 
al., 2005b).  
  
1.2.6 What is ART? 
 
Antiretroviral treatment is the main type of treatment for HIV and AIDS.  It is not a cure, but it 
can stop people from becoming ill for many years.  The treatment consists of drugs that have to 
be taken every day for the rest of a person’s life.  The main aim of antiretroviral treatment is to 
keep the amount of HIV in the body at a low level.  It stops any weakening of the immune 
system and allows it to recover from any damage that HIV might have caused already.  The 
drugs are often referred to as antiretroviral, anti-HIV, anti-Aids drugs, HIV antiretroviral drugs 
or ARVs. 
 
Taking two or more drugs at a time is called a combination therapy, dual or triple therapy.  
Taking a combination of there or more drugs is sometimes referred to as Highly Active 
Antiretroviral Therapy (HAART).  HAART are drugs that attack different parts of HIV or stop 
the virus from entering blood cells.  Even among people who respond to HAART well, the 
treatment does not get rid of HIV.  The virus continues to reproduce but at a slower pace. 
There are three different categories of ART, namely mono, dual and triple therapy.  Mono-
therapy is the Nevirapine that was given to pregnant HIV positive mothers to prevent them from 
passing the virus onto their babies.  It is no longer allowed as a single dose.   
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The dual therapy is the presently used combination of Nevirapine and AZT to prevent mother-to-
child-transmission of HIV (PMTCT).  The triple therapy is the combination of treatment for all 
people who are HIV positive.   
 
Mono-and dual-therapy is not recommended as drug resistance develops quickly, and renders 
ART unable to fight HIV as triple combination (Sunter & Whiteside, 2001).  A combination of 
pills from three different categories of ARV drugs are therefore provided in South African 
government.  All references to ART in this study will refer to triple combination therapy called 
HAART. 
 
There are five main types of ARVs: 
 Nucleoside analogue reverse transcriptase inhibitors (NRTIs), which target an 
HIV protein called reverse transcriptase. 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs), which also target 
reverse transcriptase. 
 Nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which also target 
reverse transcriptase. 
 Protease inhibitors, (PIs), which target an HIV protein called protease. 
 Fusion inhibitors, which target the point where HIV binds into cells of the 
immune system. 
Each class of drugs attacks HIV in a different way.  Generally, drugs from two (or sometimes 
three) classes are combined to ensure a powerful attack on HIV. 
 
1.2.7 Access to Antiretroviral Therapy 
 
While richer countries began to use a combination of antiretroviral therapy to effectively treat 
HIV in 1996, this treatment was for a long time only available to a small minority of South 
Africans who could afford to pay for private health care. 
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In March 2003, the TAC laid culpable homicide charges against health minister and her Trade 
and Industry colleague, claiming that they were responsible for the death of 600 HIV positive 
people a day in South Africa who had no access to antiretroviral therapy.  By this time, many 
poor African countries including Uganda, Nigeria, Zambia and Botswana were already 
implementing public treatment programmes. 
 
In November 2003, the government eventually approved plans to provide public access to the 
drug, in the form of Operational Plan for Comprehensive care and Treatment for PLHA.  The 
governments 2003 plan aimed to have 381,177 people on governments funded ARVs by 2005-
2006, only 85 000 people in the public sector were receiving treatment by September 2005 (SA, 
info.gov, 2005). 
 
The latest WHO estimate is 460 000 South Africans receiving ART at the end of 2007, equating 
to 28% of those in need of treatment (WHO, 2008).  According to government figures, around 
418 000 patients had started treatment by February 2008.  However, the pharmaceutical 
company Aspen, which makes most of the antiretroviral drugs used in South Africa, estimates 
that only 340 000-350-000 were still on treatment in Feb 2008 (others have died or stopped 
taking the drugs).  Aspen has calculated that no more than half of those who need treatment will 
be receiving it by 2009 (Business Day, 2008). 
South Africa’s national HIV treatment programme has been the topic of much debate. The South 
African government was initially hesitant about providing antiretroviral treatment to HIV-
positive people, and only started to supply the drugs in 2004 – years after many other nations had 
begun to do so – following pressure from activists. Even since 2004, the distribution of 
antiretroviral drugs has been relatively slow, with only around 28% of people in need receiving 
treatment at the end of 2007 (WHO, 2008). 
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1.3 Problem statement 
 
According to Government figures, around 418 000 people had started treatment by February 
2008.  The pharmaceutical company Aspen, which makes most of the antiretroviral drugs used in 
South Africa, estimates that only 340 000-350-000 were still on treatment in Feb 2008 (others 
died or stopped taking the drugs) .  The Aspen statement made us realize that it is very important 
to regularly observe whether people on ART are adhering to treatment (Business Day, 2008).  
This study is only investigating the adherence of antiretroviral treatment to patients taking them.  
The study also takes into consideration the factors grouped and used by WHO i.e. socioeconomic 
factors, healthcare team and system-related factors, condition-related factors, therapy-related 
factors and patient-related factors. 
 
1.4 Research design and methodology 
 
The researcher selected both interviews and questionnaires in investigating adherence for PLHA 
on ART in Durban, Ithembalabantu clinic.  These tools were both chosen because they are both 
inexpensive and allowed data collection to be done within a short period of time.  The researcher 
used a tape recorder for semi-structured interviews and questionnaires for a survey.  The study 
used theoretical sampling in selecting participants for semi-structured interviews. 
 
1.5 Purpose of the study 
 
The increased focus on ART as a strategy to mitigate the impact and further spread of HIV and 
AIDS epidemic underlines the importance of investigating obstacles to the effectiveness of ART.  
Very few studies, especially in developing countries, including SA are conducted on adherence 
to HIV treatment.   
 
It is also difficult to predict adherence to antiretroviral therapy unless you interact with the 
people who are taking them.  The study investigates the problems faced by PLHA taking 
treatment. 
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1.6 Research Objectives 
 
To determine levels and consistency of adherence. 
To determine the relationship between adherence and virologic response. 
To determine factors that influence adherence to HAART. 
 
Quantitative and qualitative methods were both used to achieve these objectives.  The data was 
collected at Ithembalabantu Clinic at Umlazi. 
 
1.7 Organization of the Research Report 
 
This thesis has been organized into six chapters.  The first chapter provides background 
information and rationale for the study as well as the aims of the research.  The second chapter 
is a review of relevant literature on adherence and factors affecting adherence.  The third 
chapter describes the research methodology used.  It discusses how the study was conducted and 
justifies the choice of data collection method used.  The fourth and fifth chapters outline the 
results of both qualitative and quantitative data analysis.  The sixth chapter offers a discussion 
of the findings and the seventh chapter is about conclusion and recommendations.  The 
conclusion summarizes the research discussed and provides recommendations for further 
research.  
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CHAPTER 2: 
LITERATURE REVIEW 
2.1 Introduction 
 
Providing successful treatment for the exceptionally growing population of HIV-related 
individuals in developing countries is one of the largest public health problems in the world.  
This concern is particularly urgent in S.A. as the country with the highest number of PLHA in 
the world (UNAIDS, 2007).  Antiretroviral treatment for HIV is starting to become increasingly 
available in developing countries.  ART have significantly improved the mortality and morbidity 
of individuals infected with HIV (Satten et al., 1998).  However, lack of adherence to HAART 
remains a key challenge to the successful management of patients with HIV and AIDS. 
 
In countries with widespread access to highly active antiretroviral therapy (HAART) has become 
a chronic manageable illness requiring long-term therapy (Liu et al., 2006).  As a result, 
maximizing patient quality of life (QOL) is now a primary focus of care and treatment strategies 
for PLWHA.  To accomplish this goal, much work has been done to characterize changes that 
occur in self-reported QOL over time and identify factors that influence the QOL (Liu et al., 
2006) in patients taking HAART. As access to HAART expands globally (UNAIDS, 2004b), 
these same issues need to be explored in resource-poor countries to form program and policy 
decisions about HAART roll-out strategies and interventions to maximize quality adjusted 
survival.   
 
Sub-Saharan Africa, which accounts for 67 % (two-thirds of the global) of all HIV infection 
(UNAIDS, 2007), is currently a major focus of HAART expansion efforts.  While several studies 
have demonstrated the feasibility and efficacy of HAART in resource-poor settings (Laniece et 
al., 2003), few have assessed whether HAART is effective at improving patients quality of time 
over time.   
 
Knowledge about factors that influence quality of life among persons taking HAART in 
resource-poor settings is extremely limited.  The gap undermines the ability of clinicians, policy 
makers and program planners functioning and well being of PLHA taking HAART.  
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On the 19 November 2003, the South African Cabinet approved the ‘Operational Plan for 
Comprehensive HIV and AIDS care Management and Treatment for South Africa’ which 
includes the provision of HAART for free in the public sector (DOH, 2003a).  The plan states 
that 1.4 million South Africans, should be able to access treatment before year 2009 (DOH, 
2003a).  In South Africa, approximately 230 000 HIV-infected individuals were receiving 
HAART, and a further 540 000 were sick with AIDS but not receiving HAART (ASSA, 2006). 
 
When aiming to provide treatment for more than a million South Africans, it is important to map 
factors determining the success of ART in the country.  The level of adherence determines the 
level of infectiousness, and how long the individual patient will live, and be productive.  This 
study focuses mainly on adherence and factors affecting adherence after commencing ART. 
 
2.2 Antiretroviral therapy and adherence 
Many studies have documented the relationship between adherence and ART and virology, 
immunologic, clinical outcomes, including progression to AIDS, occurrence of opportunistic 
infections and survival, with 95% adherence as the ‘gold standard’ (Howard et al., 2002; 
McNabb et al., 2001; Paterson et al., 2000).  In order to suppress the HIV RNA to undetectable 
levels (<50 copies/ml) the rates of adherence have to be above 95 %, but even with these 
adherence levels, some patients display detectable HIV RNA (Stone, 2001; Mannheimer et al., 
2002; Weidle et al., 2002).   
 
One study found that adherence to HAART of 80 % or greater was significantly associated with 
improved quality of life over time (Mainheimer et al., 2005) while another showed no 
association between adherence and quality of life. 
 
Several studies in United States and Europe reveal that only a minority (20-40 %) of patients are 
able to achieve such high adherence levels.  Adherence rates for ART, as measured by electronic 
monitoring, generally range from 50-80% (Arnsten et al., 2001; B; Howard et al., 2002; Paterson 
et al., 2000).  Evidence also suggests that adherence rates decrease over time.  Before 
implementation of universal access to AIDS medication, it has been hypothesized that this level 
of adherence could not be achieved in ‘developing’ nations.  Studies of adherence to ART on 
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poor resource-poor settings are limited, and the sample sizes in the existing studies are relatively 
small.  The findings from a recent systematic review indicated that adherence to ART among 
patients in sub-Saharan Africa compares favorably with adherence rates in North America: 
among the included African studies (totaling 12 116 patients, 77 % of patients achieved adequate 
adherence, while the corresponding proportion from North America was 55 % (17573 patients) 
(Singh et al., 2006).  However, the authors of the review stressed that ‘efforts to sustain 
adherence in Africa and elsewhere remain important goals to optimize outcomes for individuals 
and global treatment. 
 
One of the more concerning outcomes related to poor adherence is the development of drug-
resistant viral strains. Seth sought to define the level of adherence associated with the greatest 
risk of resistance.  Not only does poor adherence put efficacy of treatment for patient at risk, it 
also leads to the emergence drug resistance (Seth, 2004).  This in turn will compromise future 
treatment options for individuals and increase the risk exposing others to drug-viral strains.  
Non-adherence has been directly associated with treatment failures (Paterson et al., 2000), viral 
rebound and a need for regimen switching.  As treatment options are limited, this poses an urgent 
challenge.   
 
The HIV-virus mutates in response to ART (Sunter &Whiteside, 2001; Bangsberg et al., 2002b).  
How fast the virus mutates depends on the level of adherence.  Resistance develops to certain 
antiretroviral combinations (Manheimer et al., 2002).  When one is not adhering to ART, the 
drug-resistant HIV can be transmitted to sexual partners, resulting in drug-resistance in both 
partners (Chiarella et al., 2004).   
 
The prevalence of ART-resistant HIV in newly acquired infections in North America and Europe 
is estimated to range from 8-26 % (Waineberg et al., 1998).  In a study by (Kozal et al., 2004), 
15 out of 333 patients on ART were found to both have ART-resistance and engage in high risk 
sexual behavior.  These 15 patients exposed 28 partners of a negative or unknown status to HIV 
infection. 
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All interventions to promote or enhance adherence are reliant on accurate and adequate 
adherence measurement.  Such measurement has proved to be problematic.  A number of studies 
have explored adherence measurement to generate a gold standard for audit and research 
purposes.  Most adherence studies use selection (or single indicator) from five forms of 
measurement including patient self-report, doctor-report, repeat prescription filling, mechanical 
devices such as MEMS cap (MEMS view 1998) and biological markers which were claimed will 
measure drug levels directly and indirectly.  Some describe electronic devices as gold standard, 
while others use multiple measures to log adherence.  Yet electronic caps can only tell if the 
container was opened and not whether the compound was indigested.  It runs a risk of 
erroneously counting someone as adherent who opens the bottle but does not take the compound.  
It also runs the risk of counting someone as non-adherent who removes multi-doses at one time , 
takes them all at the correct time, but is only recorded on the single occasion opening the 
container.  Attempts to measure adherence, do not interfere with levels of adherence (Sherr, 
2000).  Efforts have been made to determine characteristics of patients who are particularly 
likely to be non-adherent (Simoni, et al., 2006). 
 
2.3 What factors influence adherence to antiretroviral treatment? 
Assessing adherence and providing adherence interventions in different settings requires 
formative research and use of available data before transporting instruments and interventions 
from Western cultures to developing countries.  Formative research on adherence in India can 
also lay groundwork for developing a hypothesis about adherence or generating additional 
research questions.  In India, demographic and cultural issues, such as the doctor-patient 
relationship, for example, may play a role in adherence assessment. 
 
A key determinant of antiretroviral therapy adherence is the complexity of the regimen 
(Chesney, 2000).  Factors such as pill burden (Bartlett, 2002), dietary restrictions (Stone, 2001), 
and dose frequency (McNabb, 2003) contribute to treatment complexity, thus increasing patient 
difficulty in achieving desirable adherence rates and health outcomes.  Consequently, the need 
exists for simpler regimens as combination therapies that may effectively boost patient 
medication adherence. 
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Barriers and facilitators to patients’ adherence to antiretroviral treatment in Zambia, identified 
and classified the findings into three themes, i.e. factors related to patients’ beliefs and behaviors 
such as forgetfulness, experiencing better health, busy work schedules, living alone, excessive 
alcohol consumption, beliefs about ART and side-effects; factors related to socio-economic and 
cultural factors such as stigma and discrimination, disclosure of one’s status as HIV positive, 
concerns about confidentiality, use of alternative treatments and lack of food and health service-
related factors such as lack of communication about ART between healthcare professionals and 
patients, time constraints during consultations, lack of counseling skills and patient follow up, 
lack of infrastructure to conduct counseling, and long distances to health facilities. 
 
Existing evidence from developed countries suggest that the factors influencing quality of life to 
PLHA on HAART fall into three categories: clinical, psychosocial and socio-demographic.   
Clinical outcomes associated with improved quality of life in PLHA taking HAART include 
lower CD4 cell count at HAART initiation, increased CD4 cell count over time lower initial viral 
load and presence of symptoms of HAART initiation (Nieuwkerk et al., 2001).  One study found 
that adherence of 80 % or greater was significantly associated with improve quality of life over 
time (Mainheimer et al., 2005) while another showed no association between adherence and 
quality of life (Liu et al., 2006). A number of socio-demographic factors have been associated 
with poorer quality of life among PLHA taking HAART, including old age, (Mannheimer et al., 
2005). 
 
There have been many studies examining factors associated with adherence to ART in the US 
and Europe countries where treatment has been available since mid-1990s. Generally these 
factors are categorized into (1) individual factors such as substance abuse, age, attitude towards 
treatment and psychological characteristics, (2) medication characteristics, such as dosing 
complexity, and a number pills or food requirements, (3) interpersonal characteristics, such as 
the doctor-patient relationship and other social supports and (4) the general systems within which 
care is administered (Chesney, 2000; Fogarty et al., 2002). 
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(Gehi, AK, et al., 2004) also studied the effect of adverse drugs effects and compliance and 
found that 50 % of patients in the study experienced adverse drug effects and it was the most 
common reason given for non-adherence in those patients.  Most organ systems can be affected, 
depending on the drug or class of drugs being used; proper identification of adverse effects can 
therefore be difficult. 
 
Factors that are consistently related to non-adherence include side effects and depression, poor 
social support, patient provider relations, attitudes such as mistrust, skepticism about treatment 
and medications.  Other factors have been less consistently linked to poor adherence, including 
gender, ethnicity, age, education, lack of stable housing, anxiety, regimen complexity and 
substance abuse (Gifford et al., 2000; Mehta et al., 1997). 
 
Education level and also age were identified as important predictors of compliance with ART 
therapy.  Compliance to antiretroviral medication as reported by AIDS patients assisted at the 
University Hospital of the Federal University of Mato Grosso do Sul.  Forgetfulness was the 
most common reason given by patients, followed by running out of medication.  Other predictors 
of poor adherence identified were complexity of dosing regimens and pill fatigue.  
 
Some studies found that youth (aged 18-25 years) were particularly prone to poor compliance.  
Reasons included skepticism about efficacy of medication, cost involved, stigma of disease and 
‘feeling different ‘as well as confusion about how to take the medication.  The authors concluded 
that this age group may require developmentally appropriate, empowerment-based treatment 
approaches to help with treatment difficulties and adherence. 
 
Another group prone to adherence problems is those with low literacy levels, (Kalichman, S.C., 
et al., 1999).  Nurse delivered antiretroviral treatment adherence intervention for people with low 
literacy skills and living with HIV/AIDS.  Some studies found that people living with HIV/AIDS 
who have low health literacy show poor treatment adherence and more adverse health outcomes. 
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Moyle studied compliance in an Edinburgh-based population and found that while higher 
educational level was associated with better adherence, such patients still had difficulty with 
work-time dosing as well as with depression and negative thoughts about treatment (Moyle, 
1998).  It was found that patients’ knowledge of improve CD4+count and viral load results had a 
positive impact on adherence. 
 
There are very few studies in the literature that have identified factors associated with adherence 
in Brazilian context.  Some studies conducted in Brazil have shown that adherence self-efficacy 
(belief in one’s ability to adhere), frequency of dosing, prescription literacy and medication 
beliefs were related to adherence or response to therapy outcomes (Pinheiro et al., 2002).  
Another study found that forgetfulness, alcohol use and misunderstanding were reasons given 
non-adherence by patients in an AIDS outpatient clinic of a public teaching hospital in Brazil 
(Brigido et al., 2001).  
 
2.4 Summary 
Most of the factors related to adherence were derived in quantitative studies.  The factors 
influencing adherence to ART are grouped into the same dimensions by many studies and 
reported in the same sequence as used by the World Health Organization.  Those factors are 
socio economic factors, health team and system related factors, condition-related factors, 
therapy-related factors, patient-related factors and patient-related factors. 
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CHAPTER 3 
METHODOLOGY 
 
3.1 Introduction 
The choice of methodology is guided by the objectives of the study as well as the time and 
resources available to conduct it.    Most of this chapter outlines and justifies the methods used in 
this study.  Four main phases were considered in chronological order:  (1) study design; (2) study 
setting; (3) methods of data collection and (4) methods of data analysis.  As part of data analysis, 
issues around reliability and generalizability of data were considered.  The last chapter outlines 
the limitations of the study. 
   
3.2 Study design 
Polit and Beck describe a research as an outline for conducting a study in such a way that 
maximum control will be exercised over factors that could interfere with the validity of research 
results (Polit & Beck, 2004).  The research design is the researcher’s overall plan for obtaining 
answers to research questions guiding the study.  Burns and Grove state that a research design is 
“the end results of a series of decisions made by the researcher concerning how to implement the 
study” (Burns & Grove, 2001). 
 
The triangulation research technique was chosen, as it is used to examine the phenomenon from 
multiple perspectives.  The study used a combination of quantitative and qualitative methods to 
explore the objectives of the study.  Since every method has its weaknesses, triangulation offers 
a way to strengthen the study by counterbalancing this weakness with the strength of the other 
method(s) (Jick, 1983).  Triangulation technique therefore increases the reliability and validity of 
the study.   
 
Burns and Grove refer to quantitative research as “a formal, objective and systematic process in 
which numerical data are used to obtain information about the phenomenon under study”  (Burns 
& Grove, 2001), and point out that quantitative studies seek to describe variables, examine 
relationships among variable, and determine cause-effect interaction between variables.  
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Moreover, rigour helps to identify and limit the effects of extraneous variables not under study 
(Burns and Grove, 2001).  
 
A qualitative design is structured to look for what is special and different, what distinguishes the 
case or group, what characterizes the community and its values” (Seaman, 1987).  Qualitative 
research focuses on a phenomenon that occurs in natural settings, that is, in the real world.  They 
study those phenomena in all their complexity. 
 
Little research has been conducted on ART and Adherence.  Conducting qualitative research to 
provide in-depth information on the subject will help investigating adherence to ART.  
Qualitative methods provide information on processes, activities and episodes, rather than 
statistics (Yin, 1984).  The study used phenomenological study because it focuses to a person’s 
perception of the meaning of an event.  It attempts to understand people’s perceptions, 
perspectives, and understanding of a particular situation. 
 
Time pressure, resources and financial constraints of conducting this study forced the researcher 
to conduct a cross-sectional study.  A cross-sectional study is the simplest variety of descriptive 
or observational epidemiology that can be conducted on representative samples of a population.  
It is used as a useful way to gather information. 
 
3.3 Study setting 
 
Kwazulu Natal is situated on the North Indian Ocean of South Africa.  It is densely populated 
with approximately ten million people.  The majority of the population is isiZulu speaking 
Africans.  Umlazi is situated 17 km southwest of central Durban.  It has a population of 
approximately 2.4 million, and is South Africa’s second biggest black location after Soweto.   
 
There are shack settlements surrounding Umlazi as well as backyard shacks in the township.  
The Prince Mshiyeni Hospital, a 1200 bed facility is the only main referral hospital for Umlazi’s 
21 Primary Health Care Clinics. 
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3.3.1 Study site 
The study was conducted among PLHA on ART at the Ithembalabantu Clinic at Umlazi 
Township in Durban, Kwazulu Natal, South Africa.  The name of the clinic is appropriately 
named the ‘People’s Hope’. 
 
Aids Health Foundation with local partners opened Ithembalabantu (People’s Hope clinic).  The 
clinic is located in a shopping centre in Umlazi, in an accredited VCT site with several 
counselors working in conjunction with the Kwa-zulu Natal Department of Health. Services 
provided on site include: counseling and testing; CD4 tests and lab monitoring; care and support 
(social service support and counseling); treatment education classes; antiretroviral and 
opportunistic infection treatment; and skills and capacity building classes. In September 2005, 
AHF and partners increased ART treatment to the Ithembalabantu clinic and the surrounding 
areas. In addition to scaling up the Ithembalabantu clinic, AHF established a down referral 
network involving Primary Health Clinics in the area.   
 
This system allows the Ithembalabantu clinic to test and identify more people who are living 
with HIV, refer stable clients to other local clinics, establish itself as an initiation center for more 
intensive scale-up of ART, and follow patients who experience complications with their 
regimens.   
 
It began treating its first patients in February 2002 with the goal of demonstrating the feasibility 
and effectiveness of HIV/AIDS treatment in resource-poor settings.  The intention of the US 
partner was to counsel and treat two million PLHA free of charge in SA by 2006.  The treatment 
was totally free of charge to patients, as the drugs, CD4 counts, VCT and staff salaries are 
sponsored by foreign NGOs. 
 
At the time the research was conducted, the clinic had 6169 patients on ART (Patient records, 
Ithembalabantu Clinic, 2009).  All the patients attending the clinic were African, with the 
exception of few coloureds.  The ages of PLHA on ART in the clinic ranged 18 to 62 and close 
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to 90 percent of them were unemployed (Personal conversation with M & E officer at 
Ithembalabantu Clinic, 2009).  The majority of the patients reside at Umlazi.  However, a 
substantial number of people come from other townships such as Claremont, Kwa-mashu, 
Chesterville, Umbumbulu, Kwa-makhutha, Inanda,etc. 
 
3.4 Methods of Data Collection  
The study used the triangulation technique to collect data.  Semi-structured interviews and the 
questionnaire were both used in the study.  The triangulation approach was used as an approach 
to data analysis that synthesizes data from multiple sources.  It was used because it seeks to 
quickly examine existing data to strengthen interpretations and improve policy and programs 
based on the available evidence. 
 
3.4.1 Semi-structured interviews 
The study used the in-depth, unstructured interview, which is a tool which uses an open-ended, 
discovery-oriented method that is well suited for describing both program processes and 
outcomes from the perspective of the target audience.  The semi-structured format was used.  
This format allows the skills of the interviewer to respond to the interview situation to follow 
relevant lines of enquiry.  The format is also good at collecting more factual information.   
Although it will have some pre-planned questions to ask during the interview, it also allowed 
questions to flow naturally, based on information provided by the respondent.  Therefore, a semi-
structured interview based on semi-structured interview schedule provides the best from both 
worlds.  It can capture in-depth information also allows for the collection of highly specific 
information within a narrow area of research (Seaman, 1987).  In this study, the research 
objectives are fairly narrow and the issues under investigation are clear and focused.  One could 
argue that a semi-structured interview would be more appropriate to use than an in-depth 
interview which is more open-ended and driven by the information the participant provides 
(Babbie & Mouton, 2001). 
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To ask appropriate follow-up questions, several probes were incorporated in the data collection 
tool.  The precise and understandable probes were used because they increase the likelihood of 
getting coherent and comparable information.   
 
Informal conversations with the nurses at Ithembalabantu clinic aided in the development of 
relevant probes and topics in the semi-structured interview schedule. 
 
One of the disadvantages of using the semi-structured interviews is that it can be difficult to 
control interviewees.  A semi-structured interview does not allow issues that participants find 
important to be explored openly.  This is a major constraint since the aim of an exploratory study 
is to undertake a preliminary investigation prior to a structured study of the phenomenon (De 
Vos, 1998).  Presenting a very narrow focus might prevent the initial study from providing 
enough general information that a more structured study might need.   
 
All participants were interviewed in isiZulu, since almost all PLHA attending at Ithembalabantu 
clinic are isiZulu speaking.  The semi-structured interviews were recorded using a tape recorder 
and written notes were taken. 
 
3.4.2 Survey 
Based on the information gathered in the semi-structured interviews, a survey questionnaire was 
developed.  The survey was administered face to face.  Survey research involves acquiring 
information about one or more groups of people, about their characteristics, opinions, attitudes, 
or previous experiences by asking them questions and tabulating their answers.  The other name 
for the approach is descriptive or normative survey.  Unlike a semi-structured interview, 
whereby the research may follow the standard questions with one or more individually tailored 
questions to get clarification or probe a person’s reasoning, a survey asks a standardized set of 
questions and nothing more.   
  
The strengths of a survey are that it is more structured and easy to administer.  One can manage 
to study a large sample of informants without difficulty, the data can be collected over a short 
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period of time, and one can also manage to study fairly large number of variables (Babbie & 
Mouton, 2001). 
 
 
Using a survey, one is also less likely to get ‘don’t know’ answers, and it is likely to improve the 
accuracy of the data (Struwig & Stead, 2001).  The interview has with this method the 
opportunity to clear up misunderstandings and rephrase questions to make them easier for the 
respondent to understand (Babbie, 1999). 
 
With survey questionnaires, as with several other methods, respondents might not answer 
truthfully because they cannot remember or they wish to present themselves in a socially 
acceptable manner.  Survey questionnaires also make it easier for the respondent to lie, since the 
survey only requires short answers and has no follow up questions.  This is especially important 
to keep in mind in this study, which deals with sensitive issues such as HIV/AIDS (Catania et al., 
1990). 
 
3.5 Sampling 
3.5.1 Semi-structured interviews 
Three pilot interviews were conducted to test the interview schedule.  After the interview 
schedule was developed further, 15 semi-structured interviews were conducted.  Seven of the 
participants were male, and eight were female.  The reason why there was no balance between 
both sexes was because there were 24% percent male patients in the clinic.  
 
The concept of theoretical sampling was applied when choosing participants for semi-structured 
interviews.  Theoretical sampling selects participants on the basis of relevant categories, issues, 
themes, and concepts that emerge prior to and during data collection (Strauss & Corbin, 1990).  
The objective of theoretical sampling is to uncover diversity by facilitating the identification of a 
full range of possibilities that are theoretically relevant to the research question (Strauss & 
Corbin, 1990).  The study therefore attempted to uncover diversity data within a small number of 
participants with a variety of characteristics.  In order for the study to get a good theoretical 
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sampling, participants to achieve diversity in age and time on ART were chosen.  The 
participants were only included if they fulfilled the criteria, i.e. patients who are 18 years of age 
and older and who are two months and more on ART.  The participants were recruited when they 
came into the clinic to collect their medication or having doctor’s appointments. 
 
The gold standard in a qualitative study is to saturate all themes arising from the data collected.  
If saturation was to be achieved in the study, more interviews were to be conducted until no new 
themes came up of transcripts (Strauss & Corbin, 1990).  The gold standard was not used and 
applied in this study because of time constraints and the availability of resources.   
 
The main aim of the semi-structured interviews in this study was to discover the basic categories 
and few of its properties which therefore its aim is in line with exploratory study (Glazer & 
Strauss, 1967).  It is in line with exploratory study because its aim is to uncover generalizations 
and develop hypothesis around a little known subject.  Findings should later be investigated and 
tested with more precise and more complex designs (De Vos, 1998). 
 
Since the study decided not to aim for saturation, implications for the transferability of data will 
be an issue.  There will be a chance that the other researchers conducting same studies at 
Ithembalabantu clinic might discover other categories and themes not discovered here and may 
have different answers than the ones presented here.  
 
3.5.2 Survey questionnaire 
Ten pilot questionnaires were conducted to test the effectiveness of the questions in the survey.  
After the questionnaire had been altered, 90 questionnaires were filled in.  Only patients 18 years 
and older who are taking treatment for two months or more were included in the study. The 
participants were recruited when they came into the clinic to collect their medication.  The 
participants were chosen on the basis of their willingness to participate in the study.  All those 
who were willing, fulfilled the criteria for inclusion and agreed to sign a written informed 
consent form were included in the study.  The questionnaire was only started after all the 
respondents have understood their rights and signed the informed consent form.   
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The study aimed to conduct 150 questionnaires but due to limited number of people in the 
sample population, it was difficult to find the participants who had been on ART for longer than 
two months. 
 
3.6 Methods of Analysis 
3.6.1 Semi-Structured Interviews 
After transcribing and translating the semi-structured interviews, a grounded theory approach 
was employed to analyze the qualitative data. Glaser and Strauss, the founders of grounded 
theory, came up with the constant comparative method of data analysis (Glaser & Strauss, 1967; 
Maykut & Morehouse, 1994).  This method is used to generate a theory within a new area of 
research (Maykut & Morehouse, 1994).   
 
Grounded theory is suitable for studies that have no theoretical propositions stated in the 
beginning of the project (Maykut & Morehouse, 1994).  No studies have been conducted within 
the area of ART and adherence among heterosexuals at the clinic, and little is known about the 
subject.  Grounded theory is therefore suited for this analysis. 
 
Three main steps were followed (Maykut & Morehouse, 1994).  First each line in the transcripts 
as well as the individual interviews was given a number.  This process made it possible to refer 
to all the different segments in the transcripts.  The smaller units of meaning within the data were 
then identified, which helped to define larger categories of meaning (Guba & Lincoln, 1985 – 
cited in Maykut & Morehouse, 1994).  These units of meaning were often sentences that were 
responses to certain questions.  The meaning was reviewed for recurring concepts and themes.  
From this, one prominent theme was chosen.  The utilized categories were then carefully 
examined to see which of them fell under this theme.  When no more units of meaning could be 
placed under the first theme, a second theme was chosen.  When analyzing the findings in detail, 
11 themes emerged.  A theme was introduced in the category in which it has more weight.  The 
themes were grouped into the main categories related to the objectives stated above.  These 
categories are included in chapter 4. 
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One of the great biases in open-ended interviews is the influence of the analyst’s subjectivity in 
the interpretation-phase (Babbie, 1999).  To minimize this bias, the process described above, 
were followed rigorously. 
 
3.6.2 Survey questionnaire 
The data from the survey questionnaire that were administered by face-to-face were data 
captured and cleaned using Microsoft Office Excel 2007.  The same software was used to 
analyze data. 
 
The data were re-structured and all 90 respondents were included in the analysis as they match 
the criteria and the main objectives of the variables of this study.  The study is open to error 
because of the small sample size and hence reduces generalizability.  Pivot Table Wizard in 
Excel was used to calculate frequencies and percentages. 
 
3.7 Transferability, Generalizability and Reliability 
People who are on ART clearly understand what is expected of them before they made their 
decisions about taking medication.  They attended classes which taught them about ARV 
treatment including, how and when to take them, what are the consequences of taking them as 
well as the expected behavior.  Their prior knowledge about ART and adherence can be an 
obstacle to acquiring truthful answers.   
 
Both questionnaire and interviews first asked questions about the demographic characteristics 
before adherence questions.  In the semi-structured interviews some questions were asked twice, 
but in different ways.  The consistency check was employed to increase reliability, and as a way 
to assess the accuracy of the information given by the participants. 
 
The reliability and validity of answers given by the informants was kept in mind when reading 
the interview transcripts and analyzing the collected qualitative data.  Due to the possibility of 
providing desirable answers, over reporting of adherence is likely to happen. 
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The respondents knew that they are expected to adhere to ART.  They knew that poor adherence 
to their medication will have a negative impact on their lives.  They knew that adhering to 
treatment is the right thing to do.  The danger of getting desirable answers is even greater. 
 
The survey was not aimed at generalizing on behalf of other South African people who are on 
ART because the study setting and its population are very specific.   The sample did not present 
other ART patients in other clinics providing similar services because the number of patients 
interviewed was limited, and saturation was not reached.  The semi-structured interviews would 
not for these reasons aim for transferability, which is used to judge the extent to which 
qualitative findings can be applied to other contexts (Sandelowski, 1986).   
 
As mentioned previously, the qualitative sampling and analysis used theoretical sampling, and 
through that approach rather aim to emphasize the uniqueness of human experiences and 
contexts, which thus seeks variation not repetition (Sandelowski, 1986). 
 
Even though no random sampling was employed, it could be argued that the respondents in this 
study, which constitutes of less than 10% of the patients in the clinic, are representatives of the 
clinic.  The structured interviews were therefore generalized on behalf of ART patients at 
Ithembalabantu clinic. 
 
3.8 Ethical Considerations 
The respondents who participated on this study were taking ART treatment at the clinic.  They 
were interviewed and the questionnaires were filled at the clinic while they were coming to 
collect their medication.  The respondents were sick, and suffered from a highly stigmatized 
disease.  The researcher approached the potential respondents while they were waiting for their 
medication.  The researcher made sure that they fulfilled the inclusion criteria, and then 
proceeded explaining to them the purpose of the study.  After having assured them of the 
anonymity and confidentiality, they were asked if they were willing to participate in the study.  
The respondents were then asked to read and sign the informed consent form. 
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The study did not interview or issue questionnaires to patients who had been on ART for less 
than two months as the patient might still have low CD4 count, and feel physically weak.  The 
side effects of the antiretroviral treatment can be also be more severe the first month of 
treatment.  People under 18 years of age were not interviewed as they by South African law are 
not considered adults, but part of the vulnerable group. Special ethical precautions have to be 
taken if one is to interview persons who are under the age of 18.  Ethical clearance was obtained 
from Ithembalabantu clinic. 
 
3.9 Summary 
This study employed triangulation, which involved the use of quantitative and qualitative 
methods.  The qualitative part of the study which consisted of semi-structured interviews was 
completed first.  The information gathered in 15 semi-structured interviews informed the 
development of the survey questionnaire.  In the quantitative part of the study, survey 
questionnaires were conducted face-face.  Respondents were patients at Ithembalabantu clinic at 
Umlazi outside Durban in Kwazulu-Natal. 
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CHAPTER 4 
QUALITATIVE ANALYSIS 
 
 
4.1 Introduction 
 
The study used in-depth interviews to determine the life experiences of the people living with 
HIV/AIDS who are taking ART.  An in-depth, unstructured interview is a tool which uses an 
open-ended, discovery-oriented method that is well suited for describing both program processes 
and outcomes from the perspective of the target audience.  In designing the framework to 
develop an adherence intervention that can be tailored to patients’ individual situations, 
information from the patients’ perspective is essential.  Sustaining high levels of adherence to 
antiretroviral therapy is difficult for many patients, but recent applied research among persons 
with HIV infection, including a study carried out in Barbados, offers hope (Smith, et al., 2003).  
These studies demonstrated that high levels of adherence to HAART is entirely possible with 
proper clinical management, strong patient confidence in the clinician and in the treatment, and 
effective involvement of patients as active agents in their own care and treatment. A number of 
factors have been associated with adherence to HAART and are commonly divided into five 
intersecting categories (Reiter et al., 2000) namely: patient variables, treatment regimens, disease 
characteristics, patient provider relationship and clinical setting.  The analysis of data in this 
study only used four of the intersecting categories.  
 
4.2 Characteristics of the participants 
 
The total number of participants interviewed was fifteen.  Out of the participants, seven were 
male and eight were female.  There were many female interviewed due to more female attending 
the clinic than male.  The numbers concluded to the fact that women are more at risk of 
contacting infection than men.  Of the respondents, two were between ages 20-29, four between 
ages 30-39, seven between ages 40-49, two between ages 50-59. 
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4.3 Analysis of Data 
 
4.3.1 Patient variables. 
Patient-related factors represent internal factors, including trust and belief in the therapy, the 
motivation to take therapy, knowledge of HAART and adherence, forgetting, moods and 
substance use.  Quantitative studies indicated that patients treated with HAART are motivated to 
be adherent by trust and belief in the benefit of antiretroviral therapy (Remien, et al., 2003). 
Most of the patients gave similar answers when they were asked the advantages of being on 
HAART.  Almost all of them mentioned that ART improved their health as they were attacked 
by opportunistic diseases. 
I like ARV’s.  They helped me regain my strength when I was attacked by opportunistic diseases.  
My CD4 had dropped and now it has gone up. 
       Male, age 30 
Most of the patients showed their belief in HAART.  When they were asked of the disadvantages 
of HAART, they answered that there are no disadvantages except for the problems they 
experienced during the first month of being on HAART and changes in their bodies.   
The participants seemed to know the importance of taking their medication on time.  Although 
they experienced problems and some of them still experiencing problems, it didn’t affect their 
adherence to HAART. 
I only had a problem during the first month but now I’m alright. 
       Female, age 40 
My breasts are growing bigger and bigger. 
       Female, age 28/ male, age 40 
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For some time people who are living with HIV had a problem of choosing the medication to take 
between traditional medication and ART.  Other patients even decided to use both treatments.  
When they were asked whether there was any medication they are taking besides ART, they all 
answered that they don’t take other medication other that ART and the medication prescribed by 
the doctor. 
I only take ART and vitamin tablets prescribed by Dr Mabaso only. 
      Male, 28 
 
4.3.2 Treatment regimens. 
Both qualitative and the quantitative studies showed that many patients experience side effects 
when taking HAART, and that these are an important reason for non-adherence (Sigiel, et al., 
2000). Patients choose to give the body time to rid itself of medicine and recover from the 
resulting side effects by skipping doses (Laws, et al., 2000). 
Most of the participants mentioned that they have never skipped taking their medication.  They 
know that you don’t need to take your medication after an hour of the time that you were 
supposed to take them.  One said he did not take the medication on the day he forgot because he 
knows it will do more harm than good.  All of them believed in ART relating to their state of 
conditions before they started treatment. 
The providers told me that the other medication last 12 hours in my body and the other 24 hours, 
so I make sure that I don’t skip my medication to keep the medication in my body. 
       Male, age 30 
 
I’m always carrying water with me because I have to make sure that I drink my medication 
       Female, age 51 
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Most of the participants mentioned that they experienced side effects during the first three 
months when they started ART.  Two male participants experienced problems with their libidos, 
three complained of foot cramps, the two complained that their breasts grew bigger and bigger 
everyday and the rest mentioned that they have no problems.  
The participants seemed to know the importance of taking their medication on time.  In spite of 
the problems they have about the treatment, nothing is stopping them from taking their 
medication.  
I have a libido problem, but it cannot stop me from taking medication. 
       Male, age 45 
4.3.3 Disease characteristics 
Social support was found to influence adherence to antiretroviral medication.  Support from 
family members, including children, and friends play a role in adherence to therapy (Adam, et al, 
2003).  Social support has a positive influence on adherence if it is substantial and practical, 
reminding to take medication, actually giving out medication and/or offering food and drink to 
accompany the intake of medication (Wood, et al., 2004).  By comparison, a partner who takes 
medication on different schedule or who discourages the taking of medication may lead to 
adherence problems. 
 
All the participants had taken a decision that they are taking treatment and that there is nothing 
or no one that can stop them from doing so.  Their concern and priority is prolonging their lives.  
When they were asked whether taking tablets influenced disclosure of HIV/AIDS, fourteen of 
them answered that they have disclosed their status to more than a supporter and only one 
participant disclosed only on the supporter because her sons are old and afraid to tell them, but 
they see her taking medication.  
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Although there are still signs of stigma and discrimination among our communities, it doesn’t 
stop ART patients from disclosing to at least one person. Of the women in the study, few of them 
mentioned that they were dumped by their partners after disclosing their status.  Most of them 
preferred to disclose to the family only other than friends.  They said when disclosing to other 
peoples other than the family; their status will be known by many people.   Nine of the 
participants disclosed their status after starting treatment and six disclosed before ART.   
I don’t have a problem coming here because I don’t stay here, they don’t know me. 
      Female, age 51 
I don’t care, they can see me but I’m glad I know my status and they don’t. 
      Male, age 30 
It is scary to come here but because you know why you come here, it doesn’t matter and I don’t 
care. 
      Male, age 40 
I don’t have a problem because in my neighborhood, most of us are HIV positive, besides the 
focus is my child.  He wants to be a doctor and I want to prolong my life to see him as a doctor. 
      Female 28 
All the participants have support from the people they have disclosed to and they seemed all get 
support from the families, friends and children. 
 
I told my partner, he even accompanies me to collect my medication, ask me if I took my 
medication. 
             Female, age 32  
 
My partner, who is a social worker, was the one who told me to come to the clinic and she is 
making sure I take my medication every day. 
       Male, age 40  
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4.3.4 Patient provider relationship 
The belief that good physician-patient relationship is associated with better adherence to 
antiretroviral regimen for HIV is widespread (Mehta, et al., 1997) and supported by several 
qualitative studies (Malcom, et al. 2003).    Faith in the health care provider and the experience 
of a good relationship with the health care provider that is based on trust and professional 
support seem to influence adherence positively (Golin, et al., 2002).  
 
All the participants said they are happy with the health care providers at the clinic and some of 
them said that is why they have decided to attend clinic at Ithembalabantu due to their good track 
record.  
 
They are very strict.  They become mad at you if you don’t bring your container on the day of the 
visit.  They always count the pills left to see if they correspond with the amount expected. 
       Male, age 40 
 
They took me to the counselor a couple of times because I didn’t come to collect my medication 
as per appointment.  The reason was that I wasn’t ready to take medication.  My mother told me 
to come here but now I’m coming on the expected date. 
       Female, age 28 
 
They are counting the pills from the container.  You can fool them by throwing them but at the 
end of the day, you will be fooling yourself because this is your life. 
       Male, age 30 
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4.4 Summary  
 
The findings of the qualitative study found that the people on ART are assertive about their 
status.  The results showed that they have support from their families, friends and children, the 
communication and understanding is acceptable between them and their health care providers.  
They seemed to experience side effects but they can manage them and they will not stop them 
from continuing with the medication.  Mostly they take their medication regularly because they 
know what they are doing to them and the consequences of not adhering to them.  All in all, the 
standard of adherence according to this qualitative study is acceptable. 
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CHAPTER 5 
QUANTIATIVE ANALYSIS 
 
5.1 Introduction 
 
This chapter presents the data analysis.  The questionnaire had six sections: demographic 
information, knowledge of viral load and CD 4 count, knowledge about ARV treatment, 
perception of risk of transmission, perceptions and attitudes towards ART and disclosure after 
starting ART treatment.  A total of 90 questionnaires were administered face to face with the 
respondents and a 100% response rate was obtained.  The findings resulting from the 
questionnaires were presented.  Bar, pie, column graphs and tables were used in each section of 
the questionnaire to interpret the findings. 
 
5.2 Demographic information 
This section included the respondent’s gender, age, educational level, marital status, work 
situation and known family or friends AIDS death. 
 
5.2.1 Respondent’s gender (n=90) 
 
 
Figure 5.1 
Respondent’s gender (n=90) 
 
Of the respondents, 75.56% (n=68) were females and 24.44% (n=22) were males (see figure 
5.1). 
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5.2.2 Respondent’s age (n=90) 
 
 
Figure 5.2 
Respondent’s age (n=90) 
 
Of the respondents, 3.33% (n=3) were below 21 years, 21.11% (n=19) were between 21-30 
years, 44.44% (n=40) were between 31-40 years, 22.22% (n=20) were between 41-50 and 8.89% 
(n=8) were between 51-60 years (see figure 5.2). 
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5.2.3 Respondent’s highest education (n=90) 
 
 
Figure 5.3 
Respondent’s highest education (n=90) 
 
 
Of the respondents, 5.56% (n=5) had no education, 14.44% (n=13) had primary education, 
42.22% (n=38) had secondary education, 33.33% (n=30) had grade 12 and 4.44% had diploma 
(see figure 5.3). 
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5.2.4 Respondent’s marital status (n=90) 
 
 
Figure 5.4 
Respondent’s marital status (n=90) 
 
 
Of the respondents, 65.56% (n=59) were never married, 15.56% (n=14) were married, 7.78% 
(n=7) were widowed and 11.11% (n=10) were staying with their partners (see figure 5.4). 
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5.2.5 Respondent’s work situation (n=90) 
  
 
 
Figure 5.5 
Respondent’s work situation (n=90) 
 
Of the respondents, 25.56% (n=23) were employed, 4.44% (n=4) were self employed and 
70.00% (n=63) were unemployed (see figure 5.5). 
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5.2.6 Respondent’s known family or friends AIDS death (n=90) 
 
 
 
Figure 5.6 
Respondent’s family or friend died of AIDS (n=90) 
 
Of the respondent, 78.89% (n=71) had their family members or friends died of AIDS, 20.00% 
(n=18) had no family or friend died of AIDS, and 1.11% (n=1) doesn’t know whether is there 
any friend or family died of AIDS (see figure 5.6). 
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5.3 Knowledge of viral load and CD4 count 
 
Section C of the questionnaire examined the respondent’s knowledge of the viral load and CD4 
count.  A total of 2 questions were prepared and used. 
 
5.3.1 CD4 count measure 
 
Figure 5.7 
CD4 Count Measure (n=90) 
 
Of the respondents, 8.89% (n=8) feel that CD4 measure the changing of white blood cells in the 
immune system, 6.67% (n=6) feel that CD4 measure how good the body is fighting the infection, 
65.565 (n=59) feel that CD4 measure whether the amount of virus in the blood is decreasing or 
increasing, 2.22% (n=2) don’t know what the CD4 count measure and 16.67% (n=15) feel that 
CD4 is measuring other (see figure 5.7). 
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5.3.2 Viral load measure (n=90) 
 
Figure 5.8 
Viral load measure (n=90) 
 
Of the respondents, 7.78% (n=7) feel that viral load measure the changing of white blood cells in 
the immune system, 24.44% (n=22) feel that viral load  measure whether the amount of virus in 
the blood is decreasing or increasing, 1.1% (n=1) feel that viral load measure how long your life 
will be, 3,33% (n=3) do not know what viral load measure and 63.33% (n=57) feel that viral load 
measure something else (see figure 5.8). 
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5.4 Knowledge about ARV treatment 
 
Section C of the questionnaire examined the respondent’s knowledge about ARV treatment.  A 
total of 5 questions were used. 
 
5.4.1 Knowledge about ARV treatment (n=90) 
 
ITEM 
 
 
 
True 
 
False 
Do not 
know 
 
Total 
 
N 
 
% 
 
N 
 
% 
 
n 
 
% 
 
n 
 
% 
 
1 
 
ARV’s will remove the virus from 
the body 
 
 
5 
 
5.56 
 
81
 
90.00
 
4 
 
4.44 
 
90 
 
100.00 
 
2 
 
The virus will stay hidden if I take 
my medication correctly 
 
 
86
 
95.56
 
4 
 
4.44 
 
0 
 
0 
 
90 
 
100.00 
 
3 
 
The HIV tries to trick ARV’s by 
changing its form 
 
 
64
 
71.11
 
18
 
20.00
 
8 
 
8.89 
 
90 
 
100.00 
 
4 
 
ARV’s can cure AIDS if taken few 
months after being infected 
 
 
3 
 
3.33 
 
84
 
93.33
 
3 
 
3.33 
 
90 
 
100.00 
 
5 
 
The HIV will become resistant to 
ARV’s and stop working 
 
 
39
 
43.33
 
37
 
41.11
 
14
 
15.56 
 
90 
 
100.00 
 
Table 5.1 
Knowledge of ARV treatment (n=90) 
 
Table 5.1 indicates that the majority or 90% (n=81) of the respondent said it is false that ARV’s 
will remove the virus from the body; 95.56% (n=86) said it is true that the virus will stay hidden 
in the body as long as a person is taking medication correctly; the majority of the respondents 
said it is true that HIV tries tricking the ARV by changing its form 71.11% (n=64); 93.33% 
(n=84) said it is not true that ARV’s can cure AIDS if taken few months after being infected.  
With regard to HIV becoming resistant to ARV and that ARV’s can stop working, the 
respondents were divided, with 43.33% (n=39) said it is true, 41.11% (n=37) who said it is false 
and the 15.56% (n=14) respondents feel that they don’t know the answer.  
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5.5 Perception of risk transmission 
 
Section D of the questionnaire examined the respondent’s knowledge of the risk of transmission 
of the virus 
 
5.5.1 Transmission virus more or less like while on ART compared before on ART (n=90) 
 
 
Figure 5.9 
Virus transmission (n=90) 
 
Of the respondents, 87.78% (n=79) answered that it is more likely to transmit the virus to a part 
even if you on ART or not on ART, 7.78% (n=7) answered that it is less likely that virus can be 
transmitted while on ART rather than not on ART, 2.22% (n=2) answered that the transmission 
is the same whether on ART or not on ART, 2.22% (n=2) don’t know the answer to the question 
(see figure 5.9). 
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5.5.2 The danger of sleeping without the condom (n=90)  
 
ITEM 
 
 
Very 
dangerous 
 
 
Dangerous 
Somewhat 
dangerous 
Not very 
dangerous 
Not dangerous  
Do not know 
 
Total 
 
n 
 
% 
 
N 
 
% 
 
n 
 
% 
 
N 
 
% 
 
n 
 
% 
 
n 
 
% 
 
n 
 
% 
 
1 
 
Sleep without a 
condom before 
ART 
 
 
71 
 
78.89 
 
18 
 
20.00
 
0 
 
0.00 
 
0 
 
0.0 
 
1 
 
1.11 
 
0 
 
0.00 
 
90 
 
100.00 
 
2 
 
Sleep without a 
condom after 
ART 
 
 
80 
 
88.89 
 
10 
 
 
11.11
 
 
0 
 
0.00 
 
0 
 
0.0 
 
0 
 
0.00 
 
0 
 
0.00 
 
90 
 
100.00 
 
Table 5.2 
Danger of sleeping without a condom (n=90) 
 
Table 5.2 indicates that 78.89% (n=71) answered that it is very dangerous to sleep without a 
condom before you started ARV treatment, with 20% (n=18) who also feel that it is dangerous to 
sleep without a condom before you started ARV treatment.  Out of 90 respondents, 88.89% 
(n=80) said it is very dangerous to sleep without a condom even if you are on ART treatment, 
with 11.11% (n=10) feel that it is dangerous to sleep without a condom after you started ART. 
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5.5.3 ARV’s and risks (n=90) 
 
ITEM 
 
 
 
Agree 
 
Disagree 
Do not 
know 
 
Total 
 
N 
 
% 
 
n 
 
% 
 
n 
 
% 
 
N 
 
% 
 
1 
 
Harmful to have a baby while on 
ARV’s 
 
 
49
 
54.44
 
38
 
42.22
 
3 
 
3.33 
 
90 
 
100.00 
 
2 
 
Can have a baby if my CD4 is 
above 800 
 
 
38
 
42.22
 
33
 
36.67 
 
 
19
 
21.11 
 
90 
 
100.00 
 
3 
 
Cannot have a baby with an 
unknown status 
 
 
61
 
67.78
 
28
 
31.11
 
1 
 
1.11 
 
90 
 
100.00 
 
4 
 
ARV’s reduce risk of transmission 
 
 
6 
 
6.67 
 
83
 
92.22 
 
 
1 
 
1.11 
 
 
90 
 
100.00 
 
5 
 
Treatment with ARV’s make use 
of condom less important 
 
 
0 
 
0.00 
 
 
89
 
98.89
 
1 
 
1.11 
 
 
90 
 
100.00 
 
6 
No transmission if taking ARV’s 
 
 
 
2 
 
2.22 
 
87
 
96.67
 
1 
 
1.11 
 
90 
 
100.00 
 
7 
If a cure is discovered I will stop 
using condom 
 
 
4 
 
4.44 
 
85
 
94.44
 
1 
 
1.11 
 
90 
 
100.00 
 
Table 5.3 
ARV’s and risks (n=90) 
 
Table 5.3 indicates that of the respondents,  67.78% (n=61) believed that they cannot have a 
baby if they do not know the status of the partner; 92.22 % (n=83) disagree that ARV’s can 
reduce the risk of transmission; 98.89 (n=89) disagree that treatment with ARV’s , makes using 
condoms less important; 96.67% (n=87) disagree that you cannot transmit the HIV virus to a 
partner when you are taking ARV’s assuming not using a condom; 94.44% (n=85) disagree that 
they will stop using a condom if cure for HIV virus is found.  With regard to the statement that it 
is harmful to have a baby while on ARV’s, the respondents were divided:  54.44% (n=49) agree, 
42.22% (n=38) disagree, and 3.33% (n=3) do not know the answer.   
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With regard to the statement that it is okay to have a baby if CD4 count is above 800 and the 
viral load is undetectable, also the respondents were divided: 42.22% (n=38) agree, 36.67% 
(n=33) disagree, and 21.11% (n=19) do not know the answer. 
 
5.6 Perception and attitude towards ART 
 
Section E of the questionnaire examined the respondent’s perception and attitude towards ART.  
The answers will show clearly whether the respondents adhere to the treatment by looking at 
their answers. 
 
5.6.1 Perception towards ART (n=90) 
 
ITEM 
 
 
Strongly 
agree 
 
 
Agree 
 
Undecided 
 
Disagree 
Strongly 
disagree 
 
Total 
 
n 
 
% 
 
n 
 
% 
 
N 
 
% 
 
n 
 
% 
 
n 
 
% 
 
n 
 
% 
 
1 
 
Aids less serious 
because ART 
 
 
2 
 
2.22 
 
38 
 
42.22
 
1 
 
1.11 
 
45 
 
50.00 
 
4 
 
4.44 
 
90 
 
100.00 
 
2 
 
Too early to say 
ARV’s are 
successful 
 
 
1 
 
1.11 
 
4 
 
 
4.44 
 
 
3 
 
3.33 
 
79 
 
87.78 
 
3 
 
3.33 
 
90 
 
100.00 
 
3 
With ARV’s aids 
can be 
manageable 
 
 
5 
 
5.56 
 
79 
 
87.78
 
1 
 
1.11 
 
5 
 
5.56 
 
0 
 
0.00 
 
90 
 
100.00 
 
4 
ARV’s not 
effective as meant 
to be 
 
2 
 
2.22 
 
0 
 
0.00 
 
2 
 
2.22 
 
79 
 
87.78 
 
7 
 
7.78 
 
90 
 
100.00 
 
Table 5.4 
Perception towards ART (n=90) 
 
Table 5.4 indicates that of the respondents, 87.78% (n=79) disagree that it is too early to tell if 
ARV’s will be successful in the long run; 87.78% (n=79) agree that because of ARV’s, AIDS 
can be managed like any other disease; 87.78% (n=79) disagree that ARV medication are not as 
effective as they are made to be.   
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With regard to the statement that AIDS has become a less serious illness because of ARV’s, the 
respondents were divided: 2.22 (n=2) strongly agree, 42.22% (n=38) agree, 1.11% (n=1) is 
undecided, 50.00% (n=45) disagree and 4.44% (n=4) strongly disagree. 
 
 
5.6.2 Attitude towards ART 
The following figures and statement indicates the respondents’ attitude towards ART. 
 
5.6.2.1 Days of pills missed (n=90) 
 
Figure 5.10 
Days of pills missed (n=90) 
 
Of the respondents, 81.11% (n=73) none of the pills have been missed, 14.44% (n=13) have 
missed a pill one day during the past month, 2.22% (2) have missed pills two days during the 
past month, 1.11% (n=1) have missed pills three days during the past month and 1.11% (n=1) 
have missed pills during the past month (see figure 5.10). 
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5.6.2.2 Follow medication schedule (n=90) 
 
Figure 5.11 
Medication schedule (n=90) 
 
Of the respondents, 64.44% (n=58) followed their specific schedule all of the time last month, 
33.33% (n=30) followed their specific schedule most of the time last month, 1.11% (n=1) 
followed the specific schedule about half of the time last month and 1.11% (n=1) followed the 
specific schedule some of the time last month. 
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5.6.2.3 Medication special instructions (n=90) 
 
Figure 5.12 
Medication special instructions (n=90) 
 
Of the respondents, 87.78% (n=79) answered that their medication has no special instructions 
such as take with food, on an empty stomach or with plenty of fluids; 12.22% (n=11) answered 
that their medication has special instructions. 
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5.6.2.4 How did you follow instructions last month (n=90) 
 
Figure 5.13 
Medication with special instructions (n=90) 
 
Of the respondents with special instructions on their medication, 72.73% (n=8) answered that 
they followed the instructions all of the time over the last month and 27.27% (n=3) answered that 
they followed the instruction most of the time over the last month. 
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5.6.2.5 Forgetting pills on week-ends (n=90) 
 
 
Figure 5.14 
Forgetting pills last week-end 
 
Of the respondents, 95.56% (n=86) did not forget to take medication last week-end and 4.44% 
(n=4) did forget the medication over the last week-end. 
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5.6.2.6 Last time missing medication (n=90) 
 
 
 
Figure 5.15 
When did pills missed (n=90) 
 
 
Of the respondents, 78.89% (n=71) answered that they have never missed their medication, 
5.56% (n=5) missed taking their medication more than 3 months ago, 6.67% (n=6) missed taking 
their medication 1-3 months ago, 5.56% (n=5) missed taking their medication 1-2 weeks ago and 
3.33% (n=3) within the past week. 
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5.7 Disclosure after starting ARV treatment 
 
This section of the questionnaire examined the respondent’s disclosure to their closed ones after 
they have started ARV treatment or medication.  
 
5.7.1 Family reminder (n=90) 
 
 
Figure 5.16 
Family reminder 
 
Of the respondents, 12.22% (n=11) said that they have never been reminded by their family 
members to take their medication, 4.44% (n=4) were occasionally reminded to take their 
medication, 81.11% (n=73) were always reminded to take their medication and 2.22% (n=2) said 
the statement is not applicable to them. 
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5.7.2 Have you disclosed the status to anyone? (n=90) 
 
Figure 5.17 
Status disclosure (n=90) 
 
Of all the respondents, 100% (n=90) answered that they all disclosed their status to someone 
else. 
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5.7.3 Family support (n=90) 
 
Figure 5.18 
Family support (n=90) 
 
Of the respondents, 2.22% (n=2) said they are very dissatisfied with the support that they get 
from their families, 1.11% (n=1) not satisfied or dissatisfied with the support from family, 6.67% 
(n=6) satisfied with the family support, 88.89% (n=80) are very satisfied with the support they 
get from their families and 1.11% (n=1) feel the statement is not applicable. 
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5.7.4 Status disclosure and partners (n=90) 
 
ITEM 
 
 
Strongly agree 
 
 
Agree 
Neither 
agree or 
disagree 
Disagree Strongly 
disagree 
 
Refused 
 
Total 
 
n 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
n 
 
% 
 
n 
 
% 
 
n 
 
% 
 
1 
 
No need of a 
condom if both 
HIV 
 
 
5 
 
5.56 
 
3 
 
3.33 
 
1 
 
1.11 
 
73 
 
81.11 
 
8 
 
8.89 
 
0 
 
0.00 
 
90 
 
100.00 
 
2 
 
Difficult to 
keep status a 
secret if 
staying 
together 
 
 
4 
 
4.44 
 
80 
 
 
88.89 
 
 
0 
 
0.00 
 
5 
 
5.56 
 
1 
 
1.11 
 
0 
 
0.00 
 
90 
 
100.00 
 
 
3 
ARV make it 
easier to open 
about your 
status 
 
 
 
0 
 
 
0.00 
 
 
81 
 
 
90.00 
 
 
0 
 
 
0.00 
 
 
7 
 
 
7.78 
 
 
2 
 
 
2.22 
 
 
0 
 
 
0.00 
 
 
90 
 
 
100.00 
 
 
4 
Difficult to 
insist on 
condom if 
status not 
disclosed 
 
 
1 
 
 
1.11 
 
 
75 
 
 
83.33 
 
 
3 
 
 
3.33 
 
 
11 
 
 
12.22 
 
 
0 
 
 
0.00 
 
 
0 
 
 
0.00 
 
 
90 
 
 
100.00 
 
Table 5.5 
Disclosure and partners (n=90) 
 
Of the respondents, the majority of respondents 81.11% (n=73) disagreed that there is no need to 
use a condom if both partners got HIV; 88.89% (n=80) agreed that it is difficult to keep your 
status when you are staying with a partner; 90.00% (n=81) agreed that being on ARV’s makes it 
easier to be open about your status and 83.33% (n=75) agreed that it is difficult to insist on 
condom use when you have not disclosed your status to your partner. 
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5.8 Summary 
The findings of the quantitative analysis indicated that people on ART satisfactory adhere to 
their treatment with 79% who never skipped or missed their medication.  The respondents 
indicated that they always follow their specific schedule all the time.   
 
The only problem that was shown by the analysis was the knowledge of viral load and CD 4 
count.  Most of the respondents were confusing CD 4 count with viral load with very few who 
have knowledge of both.  Most of them don’t even know why they are measured. 
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CHAPTER 6 
DISCUSSIONS OF FINDINGS 
 
6.1 Discussion 
The aim of this study was to investigate adherence for people on ART, focusing on the levels and 
consistency of adherence, the relationship between adherence and virologic response and factors 
influencing adherence to ART.  Little is known about achievable levels of antiretroviral 
treatment (ART) adherence in resource-limited settings.  This chapter contains a discussion and 
key findings of the quantitative and qualitative results presented in the two preceding chapters in 
the light of the literature review.  
There was a higher proportion of female (76%) than male (24%) in the sample.  This was mainly 
due to the fact that there were a higher proportion of female (74%) attending the clinic (Patients’ 
records, Ithembalabantu clinic, 2009).  The relatively low number of males attending the clinic 
was not surprising.  Studies have found that females are more likely to attend VCT services and 
also, actively seek health care than male (Shisana et al., 2005).  Many of the males receiving 
medication at the clinic were working.  They were therefore not able to pick up the medication 
themselves or they couldn’t wait and in a hurry to leave the clinic.  Many of the males were 
therefore not be able to participate in the study.  This exacerbated the disparity in the sample. 
This discussion will integrate the results of the quantitative and qualitative studies as 
recommendations for healthcare providers in the field of HIV.   
Adapting medication to life rather than life to medication is the first and most important strategy 
to promote adherence. Belief and education are certainly keys for adherence.  Studies have 
shown that education is a cornerstone for establishing adherence to any long term therapy 
(Eckman, et al., 1990).  HIV and antiretroviral therapy education are essential components 
needed for establishing the requisite belief in HAART that serves as a foundation for adherence 
(Tuldra, et al., 2000).   
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The quantitative analysis indicated that of the respondents, 79% said they have never missed the 
pills, 81% always reminded to take their medication which automatically concluded to the 
possible adherence and that they were able to  manage side effects.  The rapid replication and 
mutation rate of HIV, means that very high levels of adherence, >95%, are required to achieve 
the durable suppression of the viral load.  The remaining 19 % respondents that have missed 
their pills are in danger of less than 95% of the required adherence.  
The participants in the semi-structured interviews indicated that it is very important to take the 
antiretroviral drugs at the same time every day.  The respondents know why they need not to skip 
their medication.  They kept on referring to what they have been told at their four day training, 
that the other medication functions on their body for 12 hours and the others for 24 hours, 
therefore if they skip their medication, their bodies might function without medication and 
protection and the virus might get the chance to act on that moment. 
The findings on antiretroviral treatment adherence in this study were similar to the findings of 
the study adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa 
(Nachega, et al., 2004).  The study conducted a cross-sectional study of adherence among 
patients at Chris Hani Baragwanath Hospital's Adult HIV Clinic in Soweto, South Africa.   The 
study indicated that the adherence reported by patients for the month was >95% for 58 patients 
(88%), 90-95% for 6 (9%) and, < 90% for 2 (3%).  The main reasons given for missing doses 
were being away from home (30%), difficulty with the dosing schedules (23%), and running out 
of pills (12%).  Adherence decreased considerably with fear of being stigmatized by the sexual 
partner.   Plasma HIV RNA levels were <400 copies/ml in the majority of patients (73% of those 
with adherence >95% and 88% of patients with < or =95% adherence) and the overall median 
CD4 (+) cell count rose to 324/mm (3).  High adherence and viral suppression are achievable for 
a significant proportion of HIV-infected patients taking ART in a resource-limited area such as 
Soweto, South Africa.  The study suggested that strategies to maximize adherence should 
emphasize ready access to affordable and simple ART regimens, as well as HIV education 
programs to help increase awareness and decrease disease stigmatization.   
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In general, it appeared that HIV Education programs and affordable and simple ART regimens as 
suggested by the study to maximize adherence could be the solution.  The participants in the 
semi structured interviews indicated that they didn’t skip their medication because the providers 
told them from the clinic the consequences for skipping medication. 
One of the aims of this study was to determine relationship between adherence and virologic 
response.  Almost all the respondents’ files showed that their CD 4 increases and other showed 
that they are fluctuating.  The findings from the study’s survey showed that of the respondents’ 
CD 4 count, 57 (63 %) increased, 27 (30%) haven’t got their second CD 4 count results and 6 (7 
%) decreased.  The number of respondents demonstrating virologic suppression in this study is 
comparatively higher than the findings in the study ‘Predictors of suboptimal virologic response 
to highly active antiretroviral therapy among human immunodeficiency virus-infected 
adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) 
project’ (Ding, et al., 2009).  The study indicated that of the 154 adolescents enrolled in the 
study, 50 (32.5%) demonstrated early and sustained virologic suppression while receiving 
HAART. The remaining 104 adolescents (67.5%) had a poor virologic response. Adequate 
adherence (>50%)-reported by 70.8% of respondents-was associated with 60% reduced odds of 
suboptimal virologic suppression in a multivariable logistic regression model (adjusted odds 
ratio = 0.4; 95% confidence interval, 0.2-1.0). Exposure to suboptimal antiretroviral therapy 
prior to HAART, on the other hand, was associated with more than 2-fold increased odds of 
suboptimal virologic response (adjusted odds ratio = 2.6; 95% confidence interval, 1.1-5.7).  The 
study concluded that two-thirds of human immunodeficiency virus-infected adolescents in the 
current study demonstrated a suboptimal virologic response to HAART.  Non-adherence and 
prior single or dual antiretroviral therapy were associated with subsequent poor virologic 
responses to ART. 
The study ‘Antiretroviral failure despite high levels of adherence: discordant adherence-response 
relationship in Botswana’ (Bisson, 2008) argued that although adherence to antiretroviral therapy 
may be higher in sub-Saharan Africa, knowledge regarding the magnitude of adherence needed 
to maintain virological suppression in this setting is limited.   
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The findings of the study indicated that of 302 participants, 57 cases were compared with 245 
controls with respect to adherence levels on no nucleoside reverse transcriptase inhibitor-based 
HAART. Median adherence levels, as measured using pharmacy refill patterns, were consistently 
high but differed among cases and controls (91%, interquartile range 83%-97% for cases vs. 
97%, interquartile range 91%-100% for controls, P < 0.001, rank-sum test). Adherence <95% 
was independently associated with virological failure (odds ratio 4.19, 95% confidence interval 
2.2 to 8.3).  It has reported that very high rates of adherence were present in the setting, yet 
virological failure occurred nonetheless.  With the above study, it cannot be predictable that the 
6(7 %) respondents with the decreased CD 4 count is caused by skipping dose but it can be a 
virologic failure.  Future work should therefore explore other factors that might explain treatment 
failure in the setting of high levels of adherence. 
One of the aims of this study was to determine the factors influencing adherence.  When 
HAART was introduced, information on possible side effects and instructions on how to manage 
these side effects was given. It is important that possible side effects should be explained clearly 
so that patients understand properly how their medications work. During every follow-up visit, 
any ambivalence toward the medications (they heal but are also toxic) should be discussed.  All 
patients who start treatment should be prepared for the possibility of unpleasant and distressing 
side effects and advised how to handle them. 
The participants in the semi-structured interview indicated that they experienced side effects 
during their first month of starting the treatment.  Others said that they are still experiencing side 
effects such as growing breasts, feet cramps and libido problems but their side effects are not 
stopping them from adhering to their treatment. They said they are using cell phone alarms, radio 
and TV programmes as their personal reminders.   
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The patient's acceptance of being HIV positive should be discussed, as acceptance improves the 
chances of adherence.  If medically possible, it may be better to delay treatment while helping 
the patient to accept the disease.  Furthermore, a patient should be prepared for the fact that 
starting HAART can renew the confrontation with being HIV positive, which can lead to 
psychological distress and, therefore, to non-adherence.  Follow-up should be arranged to give 
support. 
Secrecy is threatened by taking treatment. The possibility of disclosure should be discussed with 
the patient as openness leads to a higher level of adherence. The fact that disclosure can lead to 
negative comments from others, which may adversely influence adherence, should also be 
discussed. If disclosure is not an option, a patient can be informed how to handle taking medicine 
in secret to prevent skipping doses.  If HIV-related symptoms are present, actions should be 
taken to diminish or manage those symptoms. 
The quantitative analysis indicated that of the respondents, all of them indicated that they have 
disclosed their status at to one person and 89% said they are satisfied with the support they get 
from their families or people that they have disclosed to.  The participants in the qualitative 
analysis indicated that they don’t care about what anyone can say about them, all they care about 
is taking care of their lives.  They all seemed to have accepted their status.  They believe in ART 
saying that they know where they are coming from before they have started ART as most of 
them were very sick, attacked by opportunistic diseases. 
Feedback about positive reactions of the body should be used to support adherence. Showing a 
decreasing viral load and an increasing CD4 cell count will build trust in the medication. As trust 
and belief can change over time with subjective experience or through information from others, 
it is necessary to discuss this theme during every follow-up visit.  Pointing out the value of 
treatment for the patient's life during follow-up visits enhances motivation. 
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Information appropriate to a patient's level of understanding will lead to the patient having 
correct knowledge of what constitutes good adherence practice. Because a patient's personal 
interpretation of good adherence practice may be based on misconceptions that are used to justify 
risky behavior, it is important to ask patients to describe their behavior and if necessary to repeat 
instructions. 
Discussing details of the circumstances that lead to forgetting medication can reveal aspects that 
need attention in order to improve adherence.  Attention should be given to personal skills, such 
as the capacity to organize one's life and one's activities and the ability to anticipate risk 
situations. 
In case of depression, a patient should be advised to undergo treatment before starting HAART.  
I n case of substance use, it is important to find a way to minimize the risk that substance use 
will remain the first priority in life.  Professional support or daily observed therapy can be an 
option. 
The quantitative analysis indicated that the respondents were confused and not sure of the 
answers about CD4 and viral load.  They did not completely understand the concept of 
infectiousness, as they did not manage to distinguish between viral load and CD 4 count.  
However, they indicated that ART made the virus decrease in their blood but never linked this to 
infectiousness and viral load.  Only 9% of the respondents gave the correct answer about why the 
CD4 is measured, 66% gave answers that showed that they are confusing CD 4 with viral load 
and the rest they gave wrong answers and 2% said they don’t know what CD4 measure. Only 
24% of the respondent gave the correct answer about why viral load is measured, with 63% 
saying the answer is not in the statement.  This showed that the participants have no appropriate 
information about CD4 and viral load and what role are these two playing in their life and ART.  
These findings identify (Marseille et al., 2002) argument as flawed, as it indicates that the 
respondents did not understand the concept of infectiousness, and that commencing ART has 
provided a reason for using condoms. 
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A trusting relationship with the healthcare provider is essential. This relationship is built on 
support and open communication. Providers should give clear instructions on how to take 
medication, explain the relationship between adherence and viral load and offer good medical 
follow-up. 
The qualitative analysis indicated that respondents have good relationship with the providers.  
All of them said the providers knows what they are doing, that they are very supportive, always 
listen to their problems and give referrals if needs be.  They all responded that they are very strict 
with adherence.   
About two participants said that the providers need you to bring the containers so they will see 
whether the amount of pills in the box corresponds with the ones expected from the box.  About 
two respondents said they have been taken to the counselor for discipline for not coming to the 
clinic to collect their medication on the expected date. 
Acquiring insight into a patient's social support systems and counseling on how to use them is a 
valuable strategy in optimizing adherence.  Social support has to be substantial and practical, 
such as reminders to take medication.  Attention should also be paid to possible negative 
influences on adherence in the patient's environment, perhaps coordinating the (medication) 
schedules of partners or dealing with a discouraging influence.  
The quantitative analysis indicated that 81 % of the respondents are always reminded to take 
their medication with 12 % who are never reminded to take their medication.  The result proves 
that the reminder to take medication plays a role in adhering to medication and should be 
emphasized to people on pre-treatment trainings. 
Some studies agreed with the factors that were analyzed in this study.  A system review of 
developed and developing nation patient-reported barriers and facilitators (Mills, et al., 2006) 
reported that in their findings, the important barriers in both settings included fear of disclosure, 
concomitant substance abuse, forgetfulness, suspicions of treatment, regimens that are too 
complicated, number of pills required, decreased quality of life, work and family responsibilities, 
falling asleep, and access to medication.  The important barriers to adherence are therefore 
consistent across multiple settings and countries. 
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The other study on barriers to antiretroviral adherence among HIV-infected adults (Murphy, 
2000) reported that the most difficult barriers for patients revealed from quantitative data were 
sleeping through dose time, problems in following special instructions, and changes in daily 
routine.   
From the qualitative data, four categories of barriers and aids to adherence emerged: patient 
characteristics, the health care provider-patient relationship, the health care system, and issues 
related to the medication regimen. 
6.2 Key findings 
The study has found relatively high levels of consistent adherence to ART among people on 
HAART.  More than70 percent of the respondents never skipped or missed their medication and 
more than 60% followed their specific schedule all the time.   The level of adherence is 
consistent with the findings from similar studies (Nachega, et al., 2004). 
Since most of the participants started ART after they were very sick, attacked by opportunistic 
diseases, ART programme could be the factor that contributes to relatively high levels of ART 
adherence. 
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CHAPTER 7 
CONCLUSION AND RECOMMENDATIONS 
 
7.1 Recommendations 
 
Based on the findings of the study, the researcher makes the following recommendations for 
practice and further research. 
 
Although the study showed the relatively high levels of adherence, the development of practical 
guidelines for implementing adherence management strategies are recommended which include, 
the issue of continuous adherence counseling; bringing treatment closer to the people; family 
care model approach to HAART,  practical reminders, adherence case management, medication 
organizer. 
 
Ithembalabantu is the only private clinic around Durban and surrounding areas also used by 
people travelling more than 50 km, therefore to avoid people not collecting their treatment at the 
stipulated dates, consideration of transport vouchers to people who genuinely cannot afford the 
cost of transport to collect their medications. 
 
The high levels of adherence does not guarantee adherence for a long time, therefore it is 
recommended that adherence be monitored uniformly with simple practical tools like pill count 
register and patient recall. Data generated should be reviewed periodically in order to know the 
rate and trend of adherence to HAART. 
 
Although participants said that they have disclosed their status to someone but they are still 
afraid for their status to be known by friends and the community because of stigma and 
discrimination.  Community mobilization aimed at mitigating stigma and discrimination should 
be sustained as this will help create an environment in which people can disclose and take 
medicines without fear. 
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There was a participant who said that their employers told him to stay home because he is not fit 
for work after disclosing to them that he is on treatment.   Rights of people in employment to 
access treatment without fear of discrimination must be protected by enforcement of appropriate 
legislations. Workplace sensitization should be done; toll free lines should be created for people 
to complain in case of violation. 
 
The study indicated that there are fewer male than female attending the clinic and that there were 
women who were dumped by their partners disclosing their status.  Program targeting men on 
HIV/AIDS issues should be emphasized. This will help increase the enrolment of men, help them 
understand the gender issues around HIV/AIDS and finally mobilize them to protectors and 
supporters of women in fight against HIV/AIDS treatment and prevention. 
 
Most of the respondents who never missed their medication reported that they use the radio and 
their cell phones as their reminders.  In order to deal with the issue of forgetfulness, radio 
stations, TV stations and mobile operators could send periodic signals with jingles reminding 
people to take their medications, therefore it should be emphasized to the patients all the time 
they visit the clinic. 
 
The feedbacks that the patients are receiving from the health care providers about the progress of 
the ARV in their bodies are important.  They will encourage them not to skip their medication 
but adhere to their medication.  The knowledge from the training sessions also the information 
appropriate to a patient's level of understanding will lead to the patient having correct knowledge 
of what constitutes good adherence practice.  Knowledge, talking and showing CD4 count and 
viral load is therefore very important as both part of the training and regular feedback during the 
time of visits to build trust of the medication. 
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Continuous operational research on adherence since adherence is dynamic.  Research is urgently 
needed to determine patient-important factors for adherence. 
 
7.2 Future research 
The following topics are recommended for further research: 
 Psychological factors and adherence to ART. 
 Socio-economic factors and adherence to ART. 
 Investigating sexual behaviors for people on ART 
 
7.3 Limitations of the study 
 
The study was only conducted in one clinic which is Ithembalabantu clinic at Umlazi.  The 
sample population used by the study was less the 10% of the people who are taking their 
medication at Ithembalabantu.  The study had a sample size of 90 respondents while the clinic 
has 6159 patients taking medication. 
 
The study used the cross sectional design.  With this design, no conclusion on causal links can be 
drawn.  It can also introduce re-call bias.  Studies have found that if patients are asked to answer 
questions concerning adherence to ART more than three months ago, the validity of the answers 
would be compromised (Graham et al., 2003). 
 
Some people were in a hurry to get back to work or they sent someone to collect their 
medication.  As a result, they couldn’t stay behind for interview and survey.  People who are 
working are therefore underrepresented in the study. 
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7.4  Conclusion 
 
The study investigated the adherence of ART to PLHA taking them at Ithembalabantu clinic, 
Umlazi.  The study found that adherence is satisfactory concluding from the sample that was 
used by the researcher.  The findings and recommendations should not serve to the patients 
taking medication at Ithembalabantu only but in the entire country. 
 
In summary, this study has found that ART through proper adherence training should provide 
another opportunity to reinforce prevention efforts and to increase HIV-positive patient’s sexual 
assertiveness.  ART does through proper adherence training, and by having a positive effect on 
patients’ health, increase the likelihood of consistent taking of medication.  However, this is an 
exploratory study and therefore it has some limitations.  Further research is needed to prove or 
refuse its findings.  Research conducted at other sites with different resources available for 
training such as public hospitals, would be especially useful. Extensive in-depth research is 
needed to explore sexual behaviors of people on ART and functions around condom use amongst 
ART patients.   
 
Longitudinal quantitative studies documenting adherence to ART over several years are needed 
to more accurately determine the consistency of patients’ adherence over years.  A longitudinal 
study is more likely to produce reliable answers as the researcher will be able to establish a better 
relationship with the patient, as well as being able to document changes in adherence over a 
period of time.    
 
The adherence rates found in this study are comparable to other studies. Most of the studies have 
adherence rates of between 70 to 90 percent adherence. 
 
HAART is predictably leads to an immunological benefit characterized by an increase in CD4 
cell count, reducing, hence, the risk of AIDS-related disease progression and death. This rate is 
low for good virologic, immunologic, and clinical outcomes. Near perfect adherence, however, is 
required to maximize the likelihood of long term clinical success.   Adherence is complex and 
multi-dimensional approach is required to tackle the barriers and strengthen the facilitators.  
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People from all groups of treated individuals commonly have difficulty maintaining a high level 
of medication adherence.  To help patients benefit fully from ART, clinicians need to take time 
to ask about and support medication adherence.  Methods to assess adherence should be used in 
clinical practice.  Methods such as patient self-report is the most simple and economical one.  
Efforts must be made to increase its sensitivity for detecting non adherence.  Efforts include 
asking about adherence regularly in an open, non judgmental and collaborative manner. 
 
There are many ways available for clinicians to support and improve medication adherence.  
Alterable factors known to affect adherence, such as depression, substance abuse, homelessness, 
regimen complexity, medication side effects, and the therapeutic relationship between patient 
and provider, can be address prior to starting therapy and in an ongoing way throughout 
treatment.  In this way adherence can be regularly assessed, problems can be addressed, side 
effects can be dealt with, medication can be simplified or changed if necessary, and adherence 
devices can be supplied where appropriate. 
 
Critical barriers that emerged from this study include forgetfulness, lack of transport fare to 
health facility, non-acceptance of status, fear of discrimination and stigma, alcohol abuse, and 
non supportive home and work environments.  
 
Though side effects occur in a significant proportion of the respondents in this study, it was not 
perceived as a barrier to adherence. The respondents showed that they were well trained to 
manage side effects. 
 
Facilitators found in this study include self efficacy, social support, perceived benefits of the 
medication, and desire to stay alive for the sake of others. Improving adherence requires a 
collaborative approach with the patient the community and health workers as well as dealing 
with and improving the environmental and structural constraints   
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Appendix/appendices 
 
ANNEXURE A: Permission letter 
 
Chairperson 
Ethics 
 
08 December 2008 
Zandile J.P School 
Sokesimbone Road 
Unit H. Umlazi 
P.O. Umlazi 
4031 
 
Dear Sir 
RE: DISSERTATION 
I hereby request permission from your office to carry out an in-depth semi-structured interview 
and a survey among PLHA who are on ART.  This is part of the requirements in order for me to 
complete my studies at the University of Stellenbosch. 
My topic is “INVESTIGATING ADHERENCE FOR PEOPLE LIVING WITH HIV AND 
AIDS ON ART IN DURBAN, KWAZULU NATAL, SOUTH AFRICA”  
                                     
Your consideration will be highly appreciated. 
 
Yours sincerely 
Mrs Nondumiso Dlomo
  
84
 
ANNEXURE B: Consent form 
 
INVESTIGATING ADHERENCE FOR PEOPLELIVING WITH HIV AND AIDS ON 
ART IN DURBAN, KWAZULU NATAL, SOUTH AFRICA 
 
Dear Mr, Mrs, Miss 
 
I am Mrs. Nondumiso Lorraine Dlomo working for KZN Department of Education, stationed at 
Zandile J.P. School, Unit H. Umlazi.  I am currently conducting research on HIV and AIDS:  
Investigating adherence for people living with HIV and AIDS on ART in Durban, Kwazulu 
Natal, South Africa.  This study is part of my master’s degree at the University of Stellenbosch, 
Cape Town and should benefit future generations in our country.  You have been selected as a 
respondent in this study.  The information collected from you will be kept confidential.  
Participation is voluntary.  Kindly tick with a cross(X) if you are willing to participate.  Do you 
want to participate? 
 
YES   
 
NO    
 
MRS NONDUMISO DLOMO 
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ANNEXURE C: Semi-structured interview 
 
GUIDE FOR INDEPTH-INTERVIEW WITH PLHA ON ANTIRETROVIRAL THERAPY 
 
Personal information 
Age      : 
Children     : 
When did you know your HIV-status? : 
When have you started ART?   : 
 
Knowledge 
1. Have you heard of ART? 
(If no, have you heard of Antiretroviral?) 
(If no, what do you call the medication that you are coming to this clinic to collect?) 
 
2. How did you hear about Ithembalabantu? 
(Probes: Was it difficult to get treatment from here? Why/ why not?) 
 
3. What do you know about ART? 
(Alternatively refer to it in the same way as the patient does). 
Probes: Why is it important to take the antiretroviral drugs at the same time every day?  What 
happens to the HIV-virus when you start taking ART?  How likely are you to infect your 
partner when you are on ART?  Does the form of the HIV-virus change when you start taking 
ART?  If yes, how can this influence your partner? 
 
4. What are some of the advantages of being on ART? 
(Probes: Has your health improved?  If yes, what impact has that had on your life?) 
 
5. What are some of the disadvantages of being on ART? 
(Probes: What side effects have you experienced?  How severe has these side effects been?  
Did you feel that you had to disclose to your family when starting to take ART?  Why/ why 
not?  Did you feel that you had to disclose to your partner when starting to take ART?  Why/ 
why not? 
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6. What type of drugs are you currently taking and how often do you take them? 
(Probes: When do you usually take them?  How do you remember to take them?  Have you 
ever change the drugs you are taking?  If yes, why?  If female and Nevirapine mentioned, why 
are you on Nevirapine?  If female and Stockrine mentioned, why are you on Stockrine? 
 
 
7. Is there any other medication you are taking besides ART?   
(If yes, what is that other medication? What is it for? Do you alternate between them and 
ART?  Do you take them at the same medications at the same time? 
 
8. How sick were you before you started ART? 
(How long have you have been sick before you started ART? What was your CD4 count 
when you started ART?  What is it now?  What training did you receive at Ithembalabantu 
before you started ART?  How long did this training last? 
   
9. How do the antiretroviral drugs make you feel? 
(Probe: Do you think the antiretroviral drugs are working?  Why/ why not? 
 
10. What made you decide to come to Ithembalabantu? 
(Probes: Do you feel stigma since only HIV-positive people come to Ithembalabantu?  Was it 
difficult to decide to come here?  What made you choose to come here rather than other 
clinic? 
 
11. How do you find providers at Ithembalabantu? 
(How strict are they with adherence?  What happens to you if you do not adhere to your 
drugs?  Does the clinic react somehow?  How is the provider’s attitude to people with HIV 
and AIDS?  How do the providers help you with your adherence to ART?) 
 
12. How did you find out about your HIV- status? 
(Probe: Was your partner sick?  Did you suspect you had HIV before you went to the doctor?  
Why/ why not?  Did you have a partner/s at the time?  If yes, was he/she/they HIV-positive?  
What has happened to this partner/s? 
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13. Do you think having to take tablets influence disclosure of HIV/AIDS?  Why/why not? 
(Probes: Have you told your family about your status?   If yes, why did you tell your family?  
How long after you find out about your status did you tell them?  How did they react?  Has 
disclosing to your family helped you?   Why/ why not?  If no, why did you not tell them?  
How do you manage to hide the drugs and going to the clinic from them?  Are you planning 
on telling your family?  Do you think your family know even though you have not told them?  
Why /why not? 
Have you told your partner/s about your status?  If yes, how long after you found out that you 
were HIV-positive did you tell him/her?  How did he/she react?  Why did you tell your 
partner?  Did you find it difficult to tell him/her?  Why/ why not?  How has the disclosure 
influenced your relationship?  How has it influence his view on HIV?  Has it made it easier 
for you to talk about HIV and ART?  Please describe the situation when you disclosed to your 
partner?  If no, why have you not told him/her?  If you were to tell him/her, would it be 
difficult?  Why/ why not?  Do you think your partner would leave you if you told him/her 
about your status?  Why/ why not?  Do you think your partner/s know even though you have 
not told him/her?  Why/ why not?   
  
14. Did you disclose your status before or after you started ART?  For those who disclosed 
only after they started ART: Why did you choose to disclose after you commenced ART? 
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ANNEXURE D: Survey questionnaire 
 
INVESTIGATING ADHERENCE FOR PEOPLE LIVING WITH HIV AND AIDS ON 
ART IN DURBAN, KWAZULU NATAL, SOUTH AFRICA. 
 
 
 
STUDY QUESTIONNARE 
 
 
 
QUESTIONNARE # : 
 
 
DATE OF SURVEY : 
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INTRODUCTION 
 
 
I am Nondumiso Dlomo, an educator from KZN Department of Education.  I am a Masters 
student at the University of Stellenbosch.  I’m conducting a study on ARV TREATMENT 
AND ADHERENCE.  I am grateful that you volunteered some of your time to answer these 
questions.  The questionnaire is strictly confidential.  The information you give and your name 
will never appear anywhere.  You are free to ask me to clarify questions if you don’t understand 
them.   The aim of this study is to investigate barriers or factors that influence adherence to 
people receiving them.  If you feel like that you don’t want to continue with the survey, you are 
free and it your right to do so.  It is important that you answer all questions honestly.  May I 
continue? 
 
Thank you. 
 
 
 
YES  
NO  
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SECTION A: DEMOGRAPHIC INFORMATION 
 
Please tick using a cross (X) in the appropriate box. 
 
1. What is your gender? 
 
 
Male Female 
1 2 
 
 
2. How old are you? 
 
 
<21 21-30 31-40 41-50 51-60 >60 
1 2 3 4 5 6 
 
 
 
3. Your highest education 
 
No 
education 
Primary 
education 
Secondary 
Education 
Grade 12 Diploma Degree 
1 2 3 4 5 6 
 
 
 
4. What is your current marital status? 
 
Single Married Widow/er Staying together 
1 2 3 4 
 
 
 
5. Which of these categories best describes your work situation? 
 
Employed Self-employed Unemployed 
1 2 3 
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6. Have a family member or any of your friends ever suffered or died of AIDS? 
 
Yes No Don’t know 
1 2 3 
   
 
 
 
SECTION B: KNOWLEDGE OF VIRAL LOAD AND CD 4 COUNT 
 
7. When did you have your first HIV test?   
 
 
 
 
 
 
  
8. When did you start ARV treatment?     
 
 
 
 
 
 
   
9. What was your CD4 count before you  
started ART? 
 
 
10. What was your CD4 count when you      
last measured it? 
 
 
11. What does the CD4 count measure? 
 
Changing 
number of 
white blood 
cells in your 
immune 
system 
Whether I 
have been 
using a 
condom or 
not 
How good is 
my body is 
at fighting 
the infection 
Whether the 
amount of 
virus in your 
blood is 
decreasing 
or 
increasing 
Do not know Other 
1 
 
2 3 4 99 98 
 
Month__________ 
Do not remember  95 
 
Year_____________ 
Do not remember  95 
 
 
Month__________ 
Do not remember  95 
 
Year_____________ 
Do not remember  95 
 
 
Specify>_____________ 
Do not remember 95 
Specify>_____________ 
Do not remember 95 
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12. What do the viral load measure?  
 
Changing 
number of 
white blood 
cells in your 
immune 
system 
Whether the 
amount of 
virus in your 
blood is 
decreasing 
or increasing 
How well my 
blood is 
How long 
your life 
will be 
Do not know Other 
1 
 
2 3 4 99 98 
 
 
 
SECTION C:  KNOWLEDGE ABOUT ARV TREATMENT 
 
Now I’m going to ask you questions concerning your knowledge about ARV treatment.  Do you 
think the following is true or false?  
 
13. When taking ARV the virus will be removed from my body? 
 
True False Do not know 
1 2 99 
 
 
14. The virus will stay hidden in my body as long as I am taking ARV correctly? 
 
True False Do not know 
1 2 99 
 
 
15. The HIV tries tricking the ARV by changing its form? 
 
True False Do not know 
1 2 99 
 
  
16. If taken within a few months after being infected, ARV can cure AIDS? 
 
True False Do not know 
1 2 99 
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17. The HIV eventually becoming resistant to ARV, and they will stop working?  
 
True False Do not know 
1 2 99 
 
 
 
  
SECTION D:  PERCEPTION OF RISK TRANSMISSION 
 
The next questions are designed to teach us more about your attitudes to HIV and ARVs.  Please 
remember there no wrong or right answers.  So fill free to tell us what you think. 
 
18. Are you more or less likely to transmit the virus to your partner now that you are on ARV 
compared to when you were not on ARV? 
 
More likely Less likely Same likelihood Do not know 
1 2 3 99 
 
 
 
19. How dangerous do you think it was for you to sleep with someone without a  
condom before you started ARV treatment? 
 
Very 
dangerous 
Dangerous Somewhat 
dangerous 
Not very 
dangerous 
Not 
dangerous 
Do not 
know 
1 2 3 4 5 99 
 
 
20. How dangerous do you think it was for you to sleep with someone without a  
condom after you started ARV treatment? 
 
Very 
dangerous 
Dangerous Somewhat 
dangerous 
Not very 
dangerous 
Not 
dangerous 
Do not 
know 
1 2 3 4 5 99 
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Do you agree or disagree with the following statements: 
 
21. It can be harmful to me and my partner if we try to have a baby while I am on ARV? 
 
Agree Disagree Do not know 
1 2 99 
 
 
22. It is ok to try to have a baby if my CD4 count is above 800 and my partner is 
HIV-positive with an undetectable viral load? 
 
Agree Disagree Do not know 
1 2 99 
 
  
23. I cannot have a baby if I do not know my partners status? 
 
Agree Disagree Do not know 
1 2 99 
 
 
24. ARV can reduce risk of transmission of infection? 
 
Agree Disagree Do not know 
1 2 99 
 
25. Treatment with ARV makes using condoms less important? 
 
Agree Disagree Do not know 
1 2 99 
 
 
26. You cannot transmit the HIV virus to your sexual partner/s when you are taking 
ARV?  Assuming you are not using condoms.  
 
Agree Disagree Do not know 
1 2 99 
 
 
27. If a cure for HIV were discovered I would stop using a condom? 
 
Agree Disagree Do not know 
1 2 99 
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SECTION E:  PERCEPTIONS AND ATTITUDES TOWARDS ART. 
 
How strongly do you agree or disagree with the following statements? 
 
28.  AIDS has become a less serious illness because of ARV? 
 
Strongly agree Agree Undecided Disagree Strongly disagree 
1 2 3 4 5 
 
 
29.  It is too early to tell if ARV will be successful in the long run? 
 
Strongly agree Agree Undecided Disagree Strongly disagree 
1 2 3 4 5 
 
 
30.  With ARV, AIDS can be managed like any other disease? 
 
Strongly agree Agree Undecided Disagree Strongly disagree 
1 2 3 4 5 
 
 
31.  ARV medications are not as effective as they are made out to be? 
 
Strongly agree Agree Undecided Disagree Strongly disagree 
1 2 3 4 5 
 
 
32.  During the past week, how many days have you missed taking your pills? 
 
None One day Two days Three days Four days 
1 2 3 4 5 
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33.  Most anti-HIV medications need to be taken on a schedule, such as “2 times a day” or 
“3 times a day” or “every 8 hours” how closely did you follow your specific schedule 
over the last week? 
 
Never Some of the 
time 
About half of 
the time 
Most of the 
time 
All of the time 
1 2 3 4 5 
 
 
34.  Does any of your anti-HIV medications have special instructions, such as “take with 
food” or “on an empty stomach” or “with plenty of fluids?” 
 
 
Yes No 
1 2 
 
 
35.  If yes, how often did you follow those special instructions over the last week?  
 
Never Some of the 
time 
About half of 
the time 
Most of the 
time 
All of the time 
1 2 3 4 5 
 
 
36.  Some of the people find that they forget to take their pills on week-ends.  Did you miss 
any of your anti-HIV medications last week-end-last Saturday or Sunday? 
 
 
Yes No 
1 2 
 
 
 
37.  When was the last time you missed any of your medication? 
 
Within past 
week 
1-2 weeks 
ago 
2-4 weeks 
ago 
1-3 months 
ago 
More than 3 
months ago 
Never skip 
1 2 3 4 5 6 
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SECTION F: DICLOSURE AFTER STARTING ARV TREATMENT 
 
38.  How often does your family remind you to take your medication? 
 
Never Occasionally Sometimes Always Not applicable 
1 2 3 4 94 
 
 
 
 
39. Have you disclose your status to anyone? 
 
Yes No 
1 2 
 
 
 
40. If yes, who have you disclosed your status to?  Multiple answers possible. 
 
 
Partner/
s 
Parent
s 
Grand 
parent
s 
Sibling
s 
Relative
s 
Friend
s 
neighbor
s 
Roommate
s 
Other 
1 2 3 4 5 6 7 8 98 
 
 
 
 
41. In general, how satisfied are you with the overall support you get from your family? 
 
 
Very 
dissatisfied 
Dissatisfied Neither 
dissatisfied 
or satisfied
Satisfied Very 
satisfied 
Do not 
know 
Not 
applicable 
1 2 3 4 5 99 94 
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Could you please indicate how strongly you agree or disagree with the following statements. 
  
 
42. When both partners got HIV, there is no need to use a condom? 
  
Strongly 
agree 
Agree Neither 
agree or 
disagree 
Disagree Strongly 
disagree 
Refused 
1 2 3 4 5 97 
 
 
 
 
43. It is difficult to keep your status a secret when you are staying with your partner? 
 
Strongly 
agree 
Agree Neither 
agree or 
disagree 
Disagree Strongly 
disagree 
Refused 
1 2 3 4 5 97 
 
 
44. Being on ARV makes it easier to be open about your status? 
 
Strongly 
agree 
Agree Neither 
agree or 
disagree 
Disagree Strongly 
disagree 
Refused 
1 2 3 4 5 97 
 
 
 
45. It is difficult to insist on condom use when you have not disclosed your status to your 
partner? 
 
Strongly 
agree 
Agree Neither 
agree or 
disagree 
Disagree Strongly 
disagree 
Refused 
1 2 3 4 5 97 
 
 
 
 
 
